Next Article in Journal
Treatment Options and Post-Treatment Malignant Transformation Rate of Actinic Cheilitis: A Systematic Review
Next Article in Special Issue
RAS Mediates BET Inhibitor-Endued Repression of Lymphoma Migration and Prognosticates a Novel Proteomics-Based Subgroup of DLBCL through Its Negative Regulator IQGAP3
Previous Article in Journal
Combined Assessment of Preoperative Frailty and Sarcopenia Allows the Prediction of Overall Survival in Patients with Lung Cancer (NSCLC) and Surgically Treated Brain Metastasis
Previous Article in Special Issue
An Overview on Diffuse Large B-Cell Lymphoma Models: Towards a Functional Genomics Approach
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 13
Issue 13
10.3390/cancers13133352
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Molecular Update and Evolving Classification of Large B-Cell Lymphoma

by
Arantza Onaindia
1,2,*,
Nancy Santiago-Quispe
2,
Erika Iglesias-Martinez
2 and
Cristina Romero-Abrio
2
1
Bioaraba Health Research Institute, Oncohaematology Research Group, 01070 Vitoria-Gasteiz, Spain
2
Osakidetza Basque Health Service, Araba University Hospital, Pathology Department, 01070 Vitoria-Gasteiz, Spain
*
Author to whom correspondence should be addressed.
Cancers 2021, 13(13), 3352; https://doi.org/10.3390/cancers13133352
Submission received: 28 May 2021 / Revised: 21 June 2021 / Accepted: 25 June 2021 / Published: 3 July 2021
(This article belongs to the Special Issue Molecular Advances in Diffuse Large B-Cell Lymphoma)
Versions Notes

Abstract

:

Simple Summary

The development of high-throughput technologies in recent years has increased our understanding of the molecular complexity of lymphomas, providing new insights into the pathogenesis of large B-cell neoplasms and identifying different molecular biomarkers with prognostic impact, that lead to the revision of the World Health Organization consensus classification of lymphomas. This review addresses the main histopathological and molecular features of large B-cells lymphomas, providing an overview of the main recent novelties introduced by the last update of the consensus classification.

Abstract

Diffuse large B-cell lymphomas (DLBCLs) are aggressive B-cell neoplasms with considerable clinical, biologic, and pathologic diversity. The application of high throughput technologies to the study of lymphomas has yielded abundant molecular data leading to the identification of distinct molecular identities and novel pathogenetic pathways. In light of this new information, newly refined diagnostic criteria have been established in the fourth edition of the World Health Organization (WHO) consensus classification of lymphomas, which was revised in 2016. This article reviews the histopathological and molecular features of the various aggressive B-cell lymphoma subtypes included in the updated classification.

1. Introduction

Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma worldwide. Patients present with a rapidly enlarging tumor mass involving single, multiple, nodal, or extranodal sites A, and approximately 40% of cases are confined to extranodal sites [1,2].
Histologically, these neoplasms are defined as the presence of lymphoma cells larger than the nuclei of histiocytes present in the same section [3,4]. DLBCL encompasses a wide spectrum of neoplasms with morphological and immunohistochemical heterogeneity. Twenty percent of cases are thought to be sufficiently different, and thirteen different variants have been accepted on the last review of the WHO organization, on the basis of distinctive morphological or immunophenotypic findings or distinctive biological issues associated with their diagnoses. However, 80% to 85% of DLBCL cases are not sufficiently distinctive and are therefore designated as not otherwise specified (DLBCL-NOS) [2,5].
A few changes have been introduced in the fourth edition of the WHO classification regarding DLBCL [2]: (1) the “cell of origin” (COO) classification must be included in the pathology report; (2) CD5, MYC, and BCL2 immunohistochemical expression must be assessed as prognostic factors; (3) the provisional entity “B cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma” has been replaced by two new categories: “high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations” and “high-grade B-cell lymphoma, not otherwise specified”.
This review focuses on the molecular update of the different DLBCL variants (Table 1 and Table 2). Viral-driven diffuse large-B cell lymphomas will not be treated in this issue.

2. Diffuse Large-B-Cell Lymphoma, Not Otherwise Specified (Dlbcl-Nos)

Diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS), accounts for about one-third of all non-Hodgkin’s lymphomas [1]. By definition, DLBCL-NOS is predominantly an aggressive lymphoma that does not belong to a specific subtype and/or variant of DLBCL [2,6]. DLBCL-NOS frequently affects elderly patients with a slight male predominance, although it can also occur in children and young adults [2,6]. Histologically, the involved tissues show diffuse infiltrates of medium- to large-sized neoplastic cells, displaying a centroblastic appearance in 80% of cases. The immunoblastic variant represents 8–10% of cases, and in the rare anaplastic variant (3% of the cases), the tumoral cells are large, bizarre, and pleomorphic [3,7].
Besides this morphologic subdivision, the COO classification has been shown to identify distinct DLBCL prognostic subgroups, with germinal center B-cell (GCB) subtype DLBCL cases (GCB-DLBCLs), representing 40–50% of DLBCL cases, being associated with a significantly better outcome compared to the activated B-cell (ABC) subgroup (ABC-DLBCL) (50–60% of DLBCL cases) [8]. Approximately 10–15% of cases cannot be included in either of these subgroups and remain unclassified [9].
Consistent with their COO, GCB-DLBCL cases harbor hypermutated immunoglobulin genes with ongoing somatic hypermutation and a high level of BCL6 expression, whereas ABC-DLBCL ones show NF-κB- and BCR-signaling-pathway activation [10]. Therefore, ABC-DLBCLs frequently harbor mutations affecting MYD88 (~20% of cases), CD79A/B (~20%), CARD11 (~10%), MALT1, BCL10, and TNFAIP3, responsible for NF-κB pathway activation [11,12]. Additionally, PRDM1/BLIMP1 mutations are also seen in 30% of DLBCL-NOS cases, exclusively in the ABC subtype. In contrast, the GCB-subtype group more often shows mutations involving histone methylation or acetylation genes (EZH2, EP300, CREBBP, KMT2D), B-cell homing genes (GNA13, GNAI2, SIPR2), the PI3K signaling pathway, and the JAK-STAT pathway. EZH2 mutations are exclusive to the GCB-type, being found in approximately 20% of cases. EZH2 mutations are gain-of-function mutations leading to an increased expression of the EZH2 protein, which is responsible for the methylation of histone H3 at lysine 27, inducing transcriptional repression and gene silencing [13,14,15,16].
The development of high-throughput technologies in recent years has increased our understanding of the molecular complexity of lymphomas beyond COO classification, defining DLBCL genetic signatures, characterizing new DLBCL subsets, and providing new insights into DLBCL pathogenesis. Initially, six genetic subgroups were defined [17,18,19]: MCD, BN2, N1, EZB, ST2, and A53. MCD and N1 cases were mostly ABC-DLBCL cases, with MYD88L265P and CD79B characterizing MCD cases and NOTCH1 mutations being present in the N1 cases. EZB and ST2 DLBCL cases were mostly GCB-DLBCLs, with recurrent BCL2 translocations and EZH2 gene mutations in the EZB subtype cases, and mutations in SGK1 and TET2 in the ST2 subtype ones [17,18]. Additionally, a worse-prognosis subtype group (A53) was also defined, with cases showing aneuploidy, TP53 mutations, and deletions [18]. Later on, whole-exome sequencing (WES) data in 304 primary DLBCLs were used by Chapuy et al. [20] to define five DLBCL subtypes (C1 to C5), allowing the distinction of both ABC and GCB-DLBCL cases in two distinct subgroups, with favorable and adverse outcomes. ABC-DLBCLs subtypes clustered in two different groups: a possible marginal zone origin one (C1) with NOTCH2 mutations, BCL6 translocation, and a lower risk, and a higher risk group one (C5) with recurrent mutations in MYD88, CD79B, and PIM1 [20]. In the same way, two different GCB-DLBCLs subtypes were also defined, including a C4 subgroup with favorable outcomes and a C3 subgroup with poor prognosis. C4 DLBCLs showed mutations affecting RAS/JAK/STAT pathway members (BRAF, STAT3), BCR/Pi3K signaling intermediates (RHOA, GNA13, and SGK1), KFkB modifiers (CARD11, NFKBIE, NFKBIA) and immune evasion molecules (CD83, CD58, and CD70) [20]. Conversely, C3 DLBCL cases harbored BCL2 mutations, as well as mutations affecting chromatin modifiers (KMT2D, CREBBP, and EZH2), B-cell transcription factors (MEF2B, IRF8), BCR-and PI3K-signaling modifiers (TNFSF14, HCNV1, GNA13), and PTEN-inactivating mutations [20]. Furthermore, a C2 subgroup associated with genomic instability, TP53 biallelic inactivation, and CDKN2A losses was also described [20].
Cytogenetic analysis is also helpful in DLBCL workup. Complex karyotypes are more common in tumors that are clinically aggressive or resistant to therapy, and specific chromosomal aberrations correlate with COO classification. The most frequent translocation (about 30% of cases) implies BCL6 at the chromosome 3q27 locus [21,22], often juxtaposed with IGH on chromosome 14q32 [3], and tends to occur more commonly in the ABC subtype [11,22]. The t(14; 18)(q21; q32)/IGH-BCL2 can be detected in the GCB type [1,7]. Translocations involving MYC at 8q24 also occur in 10–15% of DLBCL cases and are often associated with high-grade morphological features and a complex karyotype [23]. A variable proportion of the MYC translocations involve the IG loci as partners: IGH, IGK, or IGL. Other partners include non-immunoglobulin loci such as PAX5, BCL6, BCL11A, IKZF1 (IKAROS), and BTG1 [24,25].
It is recognized that GEP is not widely available [26,27], but the classic Hans algorithm utilizing antibodies against CD10, BCL6, and MUM-1/IRF4 is routinely used worldwide in COO classification [28] with variable rates of concordance (65–90%) to the GEP classification scheme. With the development of new IHC antibodies, the panel has been expanded in newer iterations, known as the “Choi”, “Tally”, and “Visco-Young” algorithms [29,30,31]. Recently, Yoon et al. [32] also demonstrated that NanoString technology for formalin-fixed, paraffin-embedded tissue may be a robust, reliable method for predicting the outcome, compared to the Hans algorithm.
Therefore, immunohistochemical assessment is mandatory for DLBCL-NOS diagnosis and COO determination, but different IHC marker expressions have been found to have prognostic significance. CD30 expression, frequently seen in the anaplastic variant of DLBCL [33,34], has been shown to be associated with a favorable outcome [34], while CD5-positive cases exhibit features associated with an aggressive clinical course and poorer survival [35]. DLBLC-NOS cases, in which MYC and BCL2 are expressed in >40% and 50% of neoplastic cells respectively, are known as double-expressor lymphomas (DEL). DEL cases are far more common in the ABC subtype and have been shown to have a worse prognosis [26]. PD-L1 and PD-L2 expression has been reported in about 20–25% of DLBCL-NOS cases, correlating with PD-L1/L2 amplification at chromosome 9p24.1 and response to PD1 inhibitors [36]. P53 expression is seen in 20–60% of cases, suggesting an upregulation of wildtype TP53 in some non-TP53 mutated cases [37].
Morphologic DLBCL variants have specific molecular features: the centroblastic variant is more frequently found in the GCB subtype, while immunoblastic lymphomas are more often found in the ABC subtype [38]. Additionally, immunoblastic lymphomas have been found to frequently harbor MYC translocations [39], which confer a worse prognosis. Li et al. [40] recently indicated the distinctiveness of the anaplastic variant based on genetic analyses. They found a higher incidence of p53 positivity (in 80% of the cases) and expression of both MYC and BCL2 (43%) in association with an aggressive clinical course.

3. High Grade B-Cell Lymphomas (Hgbl)

Morphologic distinction between Burkitt lymphoma (BL) and DLBCL is a historical diagnostic issue. However, gene-expression profiling studies have shown that BL cases exhibit a specific molecular signature, while other cases within the morphological spectrum of DLBCL and aggressive B-cell lymphomas have an intermediate molecular profile. Therefore, the so-called “grey zone lymphomas” category has been removed and replaced with two new categories: “HGBL with MYC and BCL2 and/or BCL6 rearrangements”, or “HGBL-DH/TH”, and “HGBL not otherwise specified” (HGBL, NOS) [2].

3.1. High Grade B-Cell Lymphoma with Myc and Bcl2 And/Or Bcl6 Rearrangement (Hgbl with Myc, Bcl2, And/Or Bcl6; Hgbl-Dh/Th)

DH and TH lymphomas are aggressive mature B-cell lymphomas that represents 1% to 12% of DLBCL cases [41]. Many cases morphologically resemble BL, but exhibit greater cytologic pleomorphism or an aberrant immunophenotype with a lower Ki-67 proliferation index or strong BCL2 expression, which are not characteristic of BL. By definition, HGBL DH/TH harbor rearrangements of MYC and BCL2 or BCL6 (double-hit lymphoma, DHL) or both BCL2 and BCL6 (triple-hit lymphoma; THL), detected by conventional cytogenetics or fluorescence in situ hybridization (FISH) [42].
In terms of frequency of occurrence, all three entities exhibit similar demographic, clinical, and morphological features [43,44]. The median age of affected patients is in their 6th decade with a slight male predominance, and most patients have an advanced stage disease (III/IV), with two or more sites of extranodal involvement at diagnosis [45]. Virtually any site can be involved, but bone marrow, peripheral blood, pleural effusions, central nervous system (CNS), and the gastrointestinal tract are frequently affected [45,46,47]. DH/THLs are generally refractory to standard chemotherapy regimens, and they carry a poor prognosis [48].
MYC/BCL2 DHL cases are the most frequent (60–65%), followed by MYC/BCL2/BCL6 THL cases (15–20%) and MYC/BCL6 DHL cases (10–15%) [49]. DH/THLs include cases with classical morphological DLBCL features (centroblastic, immunoblastic, and other rare variants) as well as cases with a blastoid appearance or cytologic features intermediate between BL and DLBCL [2]. Based on the COO classification, almost all DH/THL cases harboring MYC/BCL2 translocations have a GCB phenotype, whereas DHL cases with BCL6 rearrangement have been observed in both the GCB and non-GCB subtypes [41,42]. Most cases do not express TdT, but a few DHLs or THLs show unequivocal TdT expression. In the updated WHO classification scheme, it is recommended that such cases be diagnosed as B-lymphoblastic leukemia/lymphoma (B-LBL).
MYC/BCL2 DHLs show CD10, BCL2, and BCL6 expression in more than 90% of cases [50], with a ki-67 proliferation rate higher than 80% of neoplastic cells. EBER expression is almost always absent [47]. Most cases show bright CD38 expression with dim CD45 by flow cytometry in about one-third of cases [51]. Conventional cytogenetic studies of MYC/BCL2 DHLs have shown that approximately half of the translocation partners of MYC are the immunoglobulin genes. Immunoglobulin heavy chain (IGH at 14q32) is the most common YC translocation partner, followed by lambda light chain (IGL at 22q11) and kappa light chain (IGK at 2p12) in MYC/BCL2 DHL. In the other half of MYC/BCL2 DHL, MYC partners with non-immunoglobulin gene chromosomal loci, including 1p36, 3p25, 3q27(BCL6), 4p13, 5q13, 9p13 (PAX5), 12p11, and 13q31 [52,53].
Controversy exists regarding the role of the MYC partner (IG versus non-IG) in outcome, with contradictory results. McPhail et al. [54] investigated 52 cases in which the MYC rearrangement partner was an IG gene, and 35 cases in which the MYC rearrangement partner was a non-IG gene, observing no association between the MYC rearrangement partner and overall survival. Unlike the previous study, Rosenwald and colleagues [55] reported a negative prognostic impact in the MYC-IG group by initial FISH assay of MYC status. They initially tested DLBCL cases with break-apart probes, followed by testing in the rearranged cases with MYC/IG heavy chain fusion, MYC-IG kappa, and MYC-IG light fusion probes [55]. Thus, screening for MYC rearrangement with break-apart probes and further testing with MYC –IGH, IGK and IGL dual fusion probes may improve sensitivity, although with unknown prognostic impact [55,56].
Genomic complexity is high in MYC/BCL2 DHLs, with frequent gains of chromosomes 7, 8, 11, 12, 18, 20, and X, and losses of 3q27–29, 6q, and 15q26 [57]. The mutation profile of MYC/BCL2 DHLs is intermediate between BL and shows mutations affecting ID3, CCND3, MYC, and TCF3, and DLBCL of the GCB type, which harbors mutations in BCL2, EZH2, CREBBP, EP300, MEF2B, and SGK1 [58]. Evrard et al. [59] reported CREBB as the most common in MYC/BCL2 DHLs, followed by mutations affecting BCL2, KMT2D, MYC, EZH2, IGLL5, FOX01, and SOCS1. Momose and colleagues [58] also found mutations affecting ID3 and CCND3, similar to BL. TP53 mutations are also common in this subset of DH/THL, whereas they are not found in MYC/BCL6 rearranged lymphomas [23].
MYC/BCL6 DHLs show similar frequency of immunoglobulin and non-immunoglobulin MYC translocation partners as MYC/BCL2 DHL cases. MUM-1/IRF4 and BCL2 expression are variable, with less frequent CD10 expression than in MYC/BCL2 DHLs [49]. Compared to MYC/BCL2 DHLs, bright CD38 expression is present in a lower number of cases (42% of MYC/BCL6 DHL cases compared to 60% of MYC/BCL2 DHLs [49]), and BCL2, TP53, and EZH2 mutations are rare in MYC/BCL6 DHL [60].
Similar to MYC/BCL2 DHLs, immunoglobulin and non-immunoglobulin MYC translocation partners are observed almost equally [44] in THL cases. CD10 expression is more frequently found [44]. The mutation profile is similar to other DHL cases, with mutations in BCL2, CCND3, CREBBP, EZH2, ID3, KMT2D, MYC, FOXO1, and SOCS1 [58,59].

3.2. High Grade B-Cell Lymphoma, Not Otherwise Specified (Hgbcl, Nos)

High-grade B-cell lymphoma, not otherwise specified (HGBCL, NOS) comprises a heterogeneous group of aggressive mature B-cell neoplasms that do not meet the criteria for DLBCL, NOS, or BL and do not harbor double- or triple-hit genetic abnormalities [2]. On morphological grounds, two different variants have been described, including cases with features intermediate between DLBCL and BL (BCL-U) and blastoid morphology, without a genetic double- or triple-hit [2]. Cases with a BCL-U morphology are composed of a diffuse proliferation of intermediate-sized cells with a starry-sky appearance and strong mitotic activity, but that do not fit the classical BL definition either due to BCL2 diffuse immunohistochemistry expression or karyotypic abnormalities [23]. Cases with blastoid morphology resemble lymphoblasts and overlap with blastoid mantle-cell lymphomas, showing intermediate-sized cells with blastoid chromatin and a starry-sky appearance [42]. Sixty percent of cases with blastoid morphology belong to the DH/TH category, after FISH testing [42,61,62].
Several approaches have been considered for the selection of cases for further FISH testing, including KI-67 proliferation index assessment [61], MYC and BCL2 double immunohistochemical expression [41], and a COO phenotype study following the Hans algorithm [41], but none of them have been shown to be sensitive and specific enough. Therefore, FISH testing for MYC translocation is recommended in all cases with DLBCL, BCL-U, and blastoid morphology [42].
At the molecular cytogenetic level, HGBCL, NOS cases may harbor isolated MYC, BCL2, or BCL6 breakpoints. MYC is the most frequent sole rearrangement present in these neoplasms and is associated with a poor prognosis, with similar progression-free survival rate (PFS) and overall survival rate (OS) as DHL [63]. BCL2 and BCL6 can also be rearranged simultaneously without MYC rearrangement, and extra copies or the amplification of MYC, BCL2, or BCL6 [23,64] can be observed.

3.3. Burkitt Lymphoma (BL)

BL is a highly aggressive B cell NHL, representing less than 5% of adult lymphoma cases and 40% of all childhood NHL [2]. BL derives from mature germinal or post-germinal center B cells and is divided into three clinical entities, all of which present rearrangements of the MYC oncogene contributing to the overexpression of C-MYC [65]. BL may present as a leukemic form corresponding to Burkitt cell acute lymphoblastic leukemia (L3ALL), according to the revised 2016 World Health Organization (WHO) classification of hematologic malignancies [42].
Three different clinical variants of BL have been identified, sharing similar morphology, immunophenotype, and genetic features: endemic, sporadic, and immunodeficiency-related. The “endemic” variant (eBL) occurs in equatorial Africa, presenting with head and neck jaw affection and Epstein–Barr virus (EBV) infection in almost all cases [66,67]. EBL exhibits an improved outcome, with survival rates higher than 90% even in patients with central nervous system (CNS) involvement [68]. Concurrent infection with Plasmodium falciparum and EBV are regarded as the main risk factor for the development of EBL [69]. However, EBV is associated at different frequencies with sporadic BL, depending on the geographic regions [70], varying from 10 to 25% [70,71,72]. A subpopulation in southeastern Brazil was found to show an intermediate frequency of EBV infection between endemic and sporadic subtypes (60%) [72], and different studies have demonstrated that the frequency of EBV infection in HIV-associated BL cases ranges from 25% to 50% [70]. The role of EBV in BL is still unclear, and it has been suggested that EBV-positive and -negative cases might arise from different cells of origin [73].
Histologically, BL is characterized by an extremely high proliferation index (almost 100%) with a high turnover associated with a high apoptosis rate and a starry-sky appearance. The cells are intermediate in size, with a deeply basophilic cytoplasm containing small lipid vacuoles. The nuclear chromatin is granular and contains small nucleoli with frequent mitoses. Some nuclear pleomorphism is observed due to some plasmacytoid and atypical variants. BL is derived from a germinal center derived lymphoma, exhibiting BCL6, CD10, CD19, CD20, CD22, and CD79a expression and lacking CD5, BCL2, TdT, and, typically, CD23.
Virtually all cases of BL harbor a MYC translocation that causes a constitutive overexpression of the MYC oncogene. The t(8; 14) (q24; q32) is the most common chromosomal translocation, occurring in 80% of BL. It concerns the long arm of chromosome 8, the site of the MYC oncogene (8q24), and the immunoglobulin heavy chain (IGH) locus on chromosome 14. The t(2; 8)(q12;24) and t(8; 22) (q24;11), which correspond to the kappa (IGK) and lambda light chain (IGL) loci on chromosomes 2 and 22, are found in 15% and 5% of patients, respectively [74]. It is well-established that MYC translocation is not a sufficient genetic event to cause BL.
NGS techniques have provided a comprehensive analysis of the landscape of additional genetic events that contribute to BL lymphomagenesis. Burkitt lymphoma survival is dependent on “tonic” BCR signaling, which activates the PI3K pathway in BL cells, and the consequent signaling cascade promotes proliferation [10]. Approximately 70% of BL cases show constitutively active PI3K signaling [75]. This aberrant signaling results from somatic mutations in TCF3 or its negative regulator ID3, which encodes a protein that blocks TCF3 activity. Thirty-eight percent of sporadic BL cases harbor a mutation in CCDN3, which is activated by TCF3 and encodes cyclin D3, which promotes cell cycle progression [74]. Mutations of the transcription factor TCF3 or its negative regulator ID3 (DNA binding protein family) were detected in 70%, 67%, and 40% of patients with sporadic, endemic, and HIV-associated BL respectively [2,10]. Recent mutational cartography efforts in Burkitt lymphoma identified additional recurrent mutations in GNA13, RET, PIK3R1, DDX3X, FBXO11, and the SWI/SNF genes ARID1A and SMARCA4 [76].
Panea et al. [77] applied whole-genome sequencing (WSG) and transcriptome sequencing to comprehensively investigate the genome basis of all three subtypes of BL. They found that BCL7A and BCL6 genetic events were enriched in the endemic subtype, whereas DNMT1, SNTB2, and CTCF mutations occurred more frequently in HIV and sporadic patients. SNTB2 mutations were associated with EBV-negative patients, and IGLL5 and BACH2 mutations were associated with EBV-positive patients [77]. Targeting the PI3K pathway, MYC and TCF3 expression, and cell cycle kinases are among many therapeutic options to be tested in future clinical trials [78,79].
About 40% of BL acquire TP53 mutations evading MYC-induced stress signals [80]. Targeting MDM4 to alleviate the degradation of p53 can be exploited therapeutically across BL and other cancers with wild-type p53 harboring 1q gain, the most frequent copy number alteration in cancer [81]. Artesunate could also inhibit the proliferation and induce ferroptosis of BL cells in vivo, causing a significant endoplasmic reticulum stress response in the tumor cells.

3.4. Burkitt-Like Lymphoma with 11q Aberration (Bll, 11q)

Burkitt-like lymphoma with 11q aberration (BLL, 11q) is a rare diagnostic entity newly recognized as a provisional entity in the revised 4th (2017) edition of the WHO classification as a group of lymphomas resembling BL morphologically, phenotypically, and by gene and microRNA expression profiling, but lacking the characteristic MYC rearrangement seen in BL [2].
Significant morphological overlap exists between BL, DLBCL, and HGLBCL. BL11q cases show a diffuse proliferation of intermediate cells, with small nucleoli and frequent mitotic features and apoptotic bodies [82,83,84,85] imparting a starry-sky pattern similar to BL and HGLBCL, while increased pleomorphism and a lack of macrophages can assist with differential diagnosis with DLBCL [83,86,87]. However, weak MYC expression and increased LMO2 expression may be useful markers in the differential diagnosis between these entities [16,88].
NGS and DNA copy number analysis studies [14,16,75,76,89] have provided a list of genomic alterations distinguishing BL from DLBCL. Recently, Gonzalez-Farre et al. [83] identified genetic events suggesting BLL-11q is closely related to HGLBCL and DLBCL, rather than BL. This study [83] demonstrated that BLL-11q lacks ID3, TCF3, and CCND3 mutations, which are frequently found in BL, and shows, by contrast, frequent gains of 12q12-q21.1 and losses of 6q12.1-q21, which can be seen in 15% of DLBCL and IRF4-translocated lymphomas [86]. BLL-11q also shows potential specific driver mutations involving BTG2, DDX3X, ETS1, EP300, and GNA13, indicating that BLL-11q is a distinct lymphoma from BL at the molecular level [90].
However, 11q-gain/loss is not specific to this subgroup of lymphomas and can be seen in MYC-positive BL and MYC-positive (HGBL-NOS). This finding indicates that 11q aberration can be a primary or a secondary genetic change in the development of aggressive B-cell non-Hodgkin lymphoma (B-NHL) [84].

4. T-Cell/Histiocyte-Rich Large B Cell Lymphoma

T cell/histiocyte-rich large B cell lymphoma (THRLBCL) is an uncommon and aggressive variant of DLBCL [2], presenting with advanced stage disease and frequent spleen and liver involvement cells [2,91] in middle-age patients.
THRLBCL shows scattered large blasts with Hodgkin’s Reed–Sternberg cell-like nuclear features, with a popcorn-like and centroblast-like morphology, in a polymorphic background rich in epithelioid histiocytes and reactive T-cells. Neoplastic cells show pan B-cell markers (CD19, CD20, and CD79a), with BCL-6 germinal center marker expression, and PD-L1 and c-MYC positivity [2]. Background-reactive T cells show a predominance of T CD4+ cells, with a few IgD-positive B naïve cells [2,91]. Follicular dendritic cell meshwork is absent, and PD-1 positive T cells adopting a rosette configuration around tumor cells are infrequently observed [92,93].
Histological, clinical, and genetic overlap exists between NLPHL and THRLBCL, suggesting both entities may represent a biological continuum [91,94,95]. Immunoglobulin gene region studies [96,97,98] have demonstrated shared clonality between NLPHL and THRLBCL, indicating that 2% to 17% of THRLBCL come from the transformation of NLPHL [99,100]. Risk factors for transformation are not known, although variant growth NLPHL patterns (C-F) [101] with extracellular and diffuse LP patterns in a T-cell rich nodular background or a diffuse moth-eaten B-cell pattern are associated with a more advanced disease presentation [102]. Spleen involvement at time of NLPHL diagnosis might represent a risk factor for transformation [99].
A high level of genomic similarity between NLPHL and THRLBCL has also been demonstrated [94,95,103]. Gene-expression profiling (GEP) studies showed that NLPHL and THRLBCL cluster together [95] with no consistently differentially expressed genes between them [94,95,103]. UBD/FAT10 and BAT3/BAG6, both interacting with the tumor suppressor gene TP53 were found to be expressed in both entities [94,102]. Comparative genomic hybridization (CGH) studies also revealed similarities between both lymphomas, with common gains of 2p16.1 and losses of 2p11.2 and 9p11.2 [102,104]. The commonly gained region 2p16.1 includes PEX13, REL, BCL11A, PAPOLG, KIAA1841, PUS10, and LINC085 genes, while FABP1, EIF2AK3, KRCC1, THNSL2, SMYD1, FOXI3, SPATA1A7, and AQP7P1 are frequently lost. Frequent gains on the REL locus on 2p16.1, with increased REL expression have also been identified [103]. PAX5/IGH rearrangements have been reported [105], while BCL6 translocations have not been described yet in THRLBCL, as opposed to NLPHL [106]. Strong KFkB activity [95] is common in both NLPHL and THRLBCL.
Ultra-deep targeted resequencing of THRLBCL cases identified recurrent mutations with enrichment of somatic hypermutations in JUNB, DUSP2, SGK1, and SOC1 [107,108]. Tian et al. [109,110] also demonstrated EZH2 overexpression in THRLBCL, which was correlated with proliferation rate and intracellular-signaling-cascade-associated molecules p-ERK1/2, MYC, and p-STAT3.
Despite histological and molecular similarities, behavioral differences might be related to the tumor microenvironment. In the typical patterns, LP cells in NLPHL are surrounded by resetting PD1-positive T cells, with frequent CD4+ CD8+ double-positive T cells [111] and a high number of CD69+ T-cells, which are supposed to have an immunosuppressive effect by TGF-β production [112]. By contrast, THRLBCL is characterized by a decreased proportion of CD4+ cells, compared to NLPHL, and a dominant content of macrophages and dendritic cells, which have been show to create a tumor tolerogenic environment [113]. THRLBCL microenvironment’s signature, however, is hallmarked by the upregulation of CCL8, interferon-ϒ, indoleamin 2,3 dioxygenase, VSIG4, and Toll-like receptors, which are responsible for the activation of T-cells, innate immunity, and tolerogenic immune response in THRLBCL [113]. Recently, Griffin et al. [114] have reported that PD-L1/PD-L2 copy gains in neoplastic cells in up to 64% of THRLBCL cases, with an associated increase in PD-L1 expression, and clinical responses to PD-1 blockade in 60% of patients with THRLBCL.

5. Diffuse Large B-Cell Lymphoma at Specific Sites

5.1. Large B-Cell Lymphoma with Irf4 Rearrangement

Large B-cell lymphoma with IRF4 rearrangement (LBCL-IRF4) is a new provisional entity recently included in the WHO classification [2,115], which was initially described in 2011 by Salaverria et al. [116]. LBCL-IRF4 is a very infrequent neoplasm accounting for 0.05% of diffuse large B-cell lymphomas [2]; it primarily affects children and young adults with a median age of 12 years [2,116] and is characterized by a strong expression of IRF4/MUM1 and frequent IRF4 rearrangement [2].
LBCL-IRF4 usually presents with localized disease involving predominantly Waldeyer’s ring or lymph nodes of the head and neck region [2,116,117]. Only a few cases are reported involving sites below the diaphragm (abdominal lymph nodes and gastrointestinal tract [116,118]). Patients with LBCL-IRF4 have a favorable prognosis after treatment with immunochemotherapy with or without radiation [116,119].
Morphologically, most LBCL-IRF4 cases have at least a partial follicular growth pattern resembling FL grade 3B, although diffuse areas [2,119], with medium to large neoplastic cells that can show blastoid appearance and high-grade features are consistent with DLBCL. Follicular areas are characterized by large, tightly packed follicles without polarization and indistinct or absent mantle zones. A starry-sky pattern is rare and mitotic figures are present in moderate number [2].
Immunophenotypically, tumor cells express B-cell markers (CD20, CD79a, PAX5) with a strong expression of IRF4/MUM1 and BCL6 [2]. CD10 and BCL2 are shown in approximately 50% of cases [120], although it lacks t(14;18). The proliferation rate is commonly high, with no evidence of polarization in the neoplastic follicles [2,121]. Rare cases are CD5-positive, especially CD10-negative ones, though a double expression of CD5 and CD10 has been reported [122]. Some features may prompt the pathologist to suspect LBCL-IRF4: the young age of the patient, the peculiar location and histopathological pattern with typical centroblasts in follicular and diffuse growth, and the characteristic immunoprofile including the positivity of CD10, BCL6, and IRF4/MUM1 [123].
Most cases of LBCL-IRF4 are found to have a germinal center B-cell (GCB) origin, with a unique gene-expression signature [116,120]. The presence of IRF4 rearrangements identified by FISH studies, together with BCL6 rearrangements and a uniform lack of BCL2 and MYC rearrangements, are the defining features of LBCL-IRF4 [116,120,124]. Some cases may additionally exhibit IRF4/IGH fusions but are negative for IRF4 rearrangement using commercially available break-apart probes [125]. The involvement of light chain genes has been rarely reported [116]. Salaverria et al. [126] showed complex genomic changes using comparative genomic hybridization techniques, such as gains of 7q32.1-qter, 11q22.3-qter, and Xq28 and losses of 6q13–16.1, 15q14–22.3, 17p, and TP53. However, these molecular alterations were not predictors of clinical behavior. In contrast, Ramis-Zaldivar et al. [127] suggested that the underlying mutational profile may influence the morphological feature of tumors. They found that these tumors have additional mutations in NF-kB-related genes (CARD11, CD79B, and MYD88) and overexpression of genes of the KFkB pathway.

5.2. Primary Mediastinal (Thymic) Large B-Cell Lymphoma

Primary mediastinal large B-cell lymphoma (PMBL) is a distinctive clinicopathological entity with specific molecular features, accounting for 6–10% of all DLBCL, which is thought to arise from B-cells in the thymus [2,128]. PMBL affects predominantly women with a median age of 35–37 years, presenting with an enlarging often >10 cm in diameter (bulky) mediastinal mass [128] and superior vena cava syndrome. Most patients present with low stage disease (I/II), with frequent supraclavicular lymphadenopathy [129]. Histologically, PMBL is characterized by a diffuse infiltration by neoplastic cells with round or pleomorphic nuclei, pale and clear cytoplasms, and Reed–Sternberg-like cells, admixed in a sclerotic background [130].
Neoplastic cells are positive for pan-B-cell antigens, with frequent OCT-2 and BOB.1 expression, BCL6 and MUM1 expression in 95% of cases, and C-MYC and BCL2 in 65%. CD23 is observed in 70–95%, and CD30 is seen in 80% of cases [131]. PMBL is characterized by NF-kB pathway activation, with c-REL and TRAF1 expression in 65 and 62% of cases, respectively [131], as well as MAL and CD200 expression in 72 and 81%, respectively [131].
PMBL is genetically defined by the activation of different pathways, including the NF-kB, cell-cycle dysregulation, apoptosis, JAK-STAT, and immune-evasion pathways. Amplification of REL (75%) and BCL11A (50%), as well as deletions of NFKBIE (20%) and bi-allelic mutations of TNFAIP3 encoding (60%), are alterations frequently seen in PMBL dysregulating the NF-kB pathway [132,133]. Major genetic alterations involving apoptosis and cell-cycle regulation include GNA13 (50%), BCL6 (50%), and XPO1 (35%) [134]. Gains and amplifications of JAK2, PD-L1, and PD-L2, located on chromosome 9p24.1, are seen in up to 70% of PMBL cases [135], inducing PDL-1 and STAT3 overexpression. STAT6, SOCS1, PTPN1, and IL4R mutations have also been described [136,137]. Different genetic alterations contributing to immune system evasion have been reported, such as those affecting CIITA, CD58, B2, PD-L1, and PD-L2 [137,138].

5.3. Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is a rare but aggressive lymphoma, presenting with generally rapidly growing solitary or multiple ulcerated skin masses, typically on the lower legs [2], affecting elderly female patients. PCDLBCL-LT can also arise on the trunk, head–neck, and upper arms in 15% to 20% of cases [139,140]. Extracutaneous spreading has been reported with frequent lymph node, bone marrow, and central nervous system involvement [2,141,142,143,144].
Previous studies revealed an apparent worse prognosis for lesions located on the leg and for the presence of multiple skin lesions at diagnosis, with a 30–50% 5-year overall survival rate [139,140,145]. However, recent studies have reported a significantly better clinical outcome for patients when rituximab is added to a multiagent chemotherapy regimen [145,146].
Histologically, the dermis and/or subcutaneous tissue are infiltrated by diffuse sheets of medium to large centroblasts and immunoblasts [1,131], with little stromal reaction, few infiltrating small non-neoplastic lymphocytes, and frequent mitoses. The epidermis is uninvolved in most cases [141]. Pan B-cell markers are typically positive, with BCL2, BCL6, IRF4/MUM1, FOXP1, and IgM expression in most cases (>85%) [141,147,148,149,150] and a lack of CD10 immunoreactivity [139,148,150]. Up to 80% of cases exhibit c-MYC positivity, and approximately two-thirds of cases have a double-expressor phenotype [151]. Immunohistochemical expression of p63 is also variable but seen in most cases [152]. BCL-2 overexpression is associated with a chromosomal amplification of the BCL-2 gene in some cases, but t(14;18) is not usually found [153,154]. PD-L1 and PD-L2 can be expressed on a subset of cells [155].
Previous studies [156,157] have suggested that the PCDLBCL-LT mutational profile is closer to that of primary central nervous system lymphoma rather than the DLBCL subtypes. PCDLBCL-LT shows an activated B-cell (ABC) subtype genotype [158] with frequent monoclonal Ig rearrangements, somatic hypermutations, and translocations involving BCL6, MYC, and IGH [2,159].
Several gene-mutation analyses have shown mutations affecting MYD88 (up to 75% of PCDLBCL-LT cases), TNFAIP3 (~40%), and B-cell receptor pathway genes (CD79A, CD79B, CARD11), which are responsible for the constitutive activation of the NF-ƙβ pathway and ABC genotype and correlate with poorer outcome [135,160]. Assessment of MYD88 mutational status has been proposed as a useful diagnostic marker in PCLBCL-LT [160,161].
MYC translocations have been associated with a higher risk of disease progression and shortened overall survival [162]. Amplification of chromosome 18q21 region, where the BCL2 and MALT1 genes are located [154,156], loss of the CDKN2A and CDKN2B gene loci on chromosome 9p21.3, and 6q deletions with losses of the BLIMP1 gene [139,154,156] are recurrent cytogenetic events in PCDLBCL-LT.
Recently, new genomic changes, such as NFKBIE mutations and IGH-IRF8 translocation, have been found in a patient who progressed after ibrutinib treatment, and PD-L1/PD-L2 translocations have been reported in up to 40% of PCDLBCL-LT cases [156,163]. Mitteldorf et al. [164] suggested that PD-L1+ tumor microenvironment (TME) cells induce apoptosis in PD-L1+ tumor-infiltrating lymphocytes, and, therefore, direct inhibition of TME cells, particularly myeloid-derived suppressor cells, could be a promising treatment option.

5.4. Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Primary diffuse large B-cell lymphoma of the CNS (CNS-DLBCL) is a rare and aggressive subtype of DLBCL confined to the CNS (brain, spine, leptomeninges, or eyes) [2], accounting for <3% of all newly diagnosed intracranial neoplasms and <1% of all non-Hodgkin lymphomas [165,166,167].
CNS-DLBCL shows a diffuse proliferation of large atypical lymphoid cells with a perivascular growth pattern and large areas of geographical necrosis, with immunoblastic, centroblastic, or anaplastic features, and with a prominent astrocytic and microglial activation [2,168]. The neoplastic cells express pan B-cell markers (PAX5, CD19, CD20, CD79a). Most CNS-DLBCLs exhibit a non-germinal B-cell immunophenotype (non-GCB) according to the Hans classification, with BCL6 and MUM1 expression in 60–80% of cases and 90%, respectively [169,170].
MYC, BCL2, and BCL6 translocations have been related to an aggressive clinical course and response to conventional chemotherapies [171,172,173,174]. Lower frequencies of these rearrangements in CNS-DLBCL compared to systemic DLBCL suggest that brain environment may play an important role in its pathogenesis [171,172,173,174].
On the other hand, the expression of histone methyltransferase EZH2 has been found in 20% of germinal center B-cell-like (GCB) DLBCLs and plays an important role in its tumorigenesis [175,176]. Guo et al. [177] revealed that EZH2 is strongly expressed in primary CNS-DLBCL, with no evidence of Y641 mutation [177,178].
Recurrent copy number abnormalities have also been described, including gains of genetic material affecting the 18q21.33–23 regions, which includes the BCL2 and MALT1 genes, as well as the 10q23.21 region in chromosome 12. Deletions of 6p21, 6q, and 9p21.3 have also been described [2,179,180].
Advances in NGS have enabled the effectiveness and comprehensive analysis of the molecular composition and function of CNS-DLBCL. In some cases, these mutations affect potential therapeutic targets and provide new opportunities for personalized therapies. Mutations have been categorized into eight cellular pathways: NF-kB (PIM1, MYD88, IRF4, CARD11), B-cell receptor (CD79B, CD79A, ITPKB), epigenetic modulation (KMT2D, CREBBP, MEF2B), JAK-STAT (CCND1, SOCS1, STAT6, STAT3), NOTCH1/2, immune related (CD58, CIITA), PI3K-AKT, and apoptotic regulation (GNA13, MYC, RHOA, BCL2) [181,182]. The most commonly mutated genes include MYD88, which is found in more than half of the cases [183], PIM1, CD79B, and CDKN2A [181,184]. Lionakis et al. [185] showed that the MYD88 and CD79B pathways targeted with ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to enhance the efficacy of chemotherapy. Balint et al. [186] also pointed out the potential role of mutations affecting the PTEN and SMO genes in CNS-DLBCL pathogenesis, as well as their correlation with inferior overall survival. Zheng et al. [187] showed that 37% of their cases had methylation in the promoter in exon 1 of the MGMT gene. Thus, targeting the MGMT protein could represent a potential drug target for novel agents in the treatment of this aggressive lymphoma. TP53 mutation status in CNS-DLBCL remains unclear. A few studies revealed incidences <10% [188,189], while, paradoxically, other investigations show higher rates (29–79%) of p53 protein expression by immunohistochemistry [190,191,192,193].
Rare CNS-DLBCL cases occur in an immunosuppression context with frequent EBV infection and association with a dismal outcome. EBV-positive cases lack the frequent mutations found in the MYD88, CD79B, and PIM1 genes in the EBV-negative cases, and rarely showed copy number loss in HLA class I/II and antigen-presenting/-processing genes [194]. These results suggested a different pathobiological origin between EBV-positive and -negative CNS-DLBCLs [194].
CNS-DLBCL is an entity distinct from systemic DLBCL. Moreover, because it resides in an immune-privileged site, CNS-DLBCL may have a different immune microenvironment. Kim et al. [174] investigated PD-L1 immunostaining expression on tumor and non-tumoral cells, as well as the presence of PD-1+ and CD8+ tumor-infiltrating lymphocytes (TILs). PD-L1 was either frequently expressed in tumor cells and the microenvironment or further positively correlated with increased TILs. Frequent copy number gains at chromosome 9p24.1, which includes the programmed death ligand 1 and 2 (PD-L1/PD-L2) locus, have been reported [179,195,196]. Up to 30% of patients showed PD-L1 expression by the neoplastic cells in the study performed by Nayyar et al. [182], despite not identifying copy gains of PD-L1/PD-L2. As we mentioned previously, tumoral PD-L1 expression has been described to be associated with a worse prognosis, and a large number of CD8+ or PD-1+ TILs have been associated with a favorable outcome. According to Furuse et al. [197], PD-L1 expression on peritumoral macrophages is correlated with longer overall survival.
These recent molecular insights into the underlying genomic alterations are relevant to the CNS-DLBCL clinical trials for refractory or relapsed cases that are currently assessing the efficacy of small molecules. Immune checkpoint inhibitors, rapamycin or immunomodulatory drugs (IMiDs), targeting the PI3K/mammalian (mTOR) pathway and BCR/TLR pathways, respectively, show promising clinical responses [198,199].

6. Large B Cell Lymphomas with Plasmacytic Differentiation

6.1. ALK-Positive Large B-Cell Lymphoma

ALK-positive large B-cell lymphoma (ALK+ DLBCL) is a newly recognized entity by the fourth edition of the WHO [2] because of its distinct characteristics and clinicopathological significance [2]. ALK+ DLBCL is a rare and aggressive form of B-cell lymphoma exhibiting plasmablastic differentiation, which was initially described in 1997 by Delson and colleagues [200] as an immunoblastic or plasmablastic large cell lymphoma with constant ALK immunohistochemical expression. Histologically, ALK+ DLBCL shows a sinusoidal growth pattern, plasmacytic and T-cell lineage markers with CD30 and single light-chain cytoplasmic immunoglobulin A (IgA) expression, and a lack of CD20 and CD79α markers.
As mentioned above, ALK immunohistochemical expression is a constant finding in ALK + DLBCK, showing different patterns according to the underlying gene rearrangement.
Firstly, molecular and protein analyses failed to reveal an ALK gene rearrangement, but later studies demonstrated that most ALK+ DLBCL harbor the t(2;17)(p23;q23) translocation, which results in the fusion of the ALK gene at chromosome band 2p23 and the clathrin gene (CLTC) at 17q2.clathrin (CLTC), in 85–90% of the cases [201,202], and more rarely, the t(2;5)(p23;q35), which results in the nucleophosmin (NPM)-ALK fusion gene, which characterizes up to 75% of the anaplastic large T cell lymphomas (ALCL) [203,204]. Stachursky et al. [205] also identified a cryptic insertion of the ALK gene into chromosome 4 at band 4q22–24, and additional ALK partner genes have been identified, including SEC31A, SQSTM1, RANBP2, and IGL [203,204,206,207].
NPM-ALK, CLTC-ALK, and SQSTM1-ALK translocations lead to ALK and STAT3 phosphorylation [207] with downstream oncogenic activation of the transcription factor STAT3, which enhances lymphoma cell proliferation and growth. Consequently, STAT3 inhibition provides a possible therapeutic target al.so for ALK + DLBCL [207].

6.2. Intravascular Large B-Cell Lymphoma

Intravascular large B-cell lymphoma (IVLBCL) is a rare type of extranodal large B-cell lymphoma characterized by the selective growth of malignant B-cells within the lumina of vessels [2], without nodal or extranodal involvement, occurring in adults. By the time of presentation most patients have advanced, disseminated disease, and the clinical diagnosis is often made at autopsy [208].
The fourth edition of the WHO Classification established two major clinical variants of IVLBCL, the classic and hemophagocytic syndrome-associated forms, but Narittee and colleagues proposed a cutaneous form [131]. Patients with the classic form (Western countries) present symptoms related to the main organ involved, particularly the skin and the central nervous system. The hemophagocytic syndrome-associated form (Asian variant) is characterized by multiorgan failure, pancytopenias, and hepatosplenomegaly. The cutaneous form is confined to the skin, and it has been identified in Western females and is associated with a better prognosis [2,131]. B symptoms, especially fever (45%), are very common, as well as laboratory abnormalities like high serum lactate dehydrogenase (LDH) and soluble IL-2 receptor (sIL-2R) levels [2,131].
Microscopically, the neoplastic lymphoid cells are medium to large size, with prominent nucleoli, scant cytoplasm, and frequent mitotic figures [2,131,208]. Tumor cells express mature B-cell antigens, and about 30% of cases are CD5 positive [2,131,208]. CD10 (10%), BCL-2 (90%), C-MYC (70%), IRF4/MUM-1 (75%), and BCL-6 (25–60%) can also be positive. Ki-67 is usually high, from 60% to 100%. PD-L1 can be positive in 44–50% of cases in any clinical variant [131].
WES results recently showed an ABC-DLBC-like molecular signature, with higher frequencies of mutations in MYD88, CD79B, SETD1B, and HLA-B compared to nodal DLBCLs, as well as PD-L1/PD-L2 rearrangements and PD-L1 overexpression [209]. Immunoglobulin genes are clonally rearranged, and karyotypic abnormalities have been described [2] in chromosome 1 (72%), 3, 6q, 14, and 18, as have mutations in PIM1 (67%), MYD88 (44–59%), CD79B (26–67%), PRDM1 (44%), BTG2 (22%), and EZH2 (4%) [2,131,208]. A defect in homing receptors on the neoplastic cells, such as the lack of CD29 (integrin beta-1) and CD54 (ICAM1) adhesion beta-molecules, might explain the intravascular location [2,131].

7. Conclusions

New advances in molecular technologies have yielded a tremendous amount of information about lymphoma biology, leading to a refined classification of lymphomas, which is reflected in the revised fourth edition of the WHO classification. Lymphoma diagnosis currently integrates clinical information, morphology, immunophenotypic, and genetic data. This review focuses on specific variants of DLBCL with unique features and for which recognition is important for diagnosis and therapeutic management, as well as on the large category of DLBCL-NOS that represents 80% of all DLBCL cases.

Author Contributions

A.O., N.S.-Q., E.I.-M. and C.R.-A. wrote the manuscript and contributed to manuscript revision. All authors have read and agreed to the published version of the manuscript.

Funding

No funding was received.

Acknowledgments

We would like to thank Bioaraba Health Research Institute.

Conflicts of Interest

The authors declare that they have no competing interest.

References

  1. Xie, Y.; Pittaluga, S.; Jaffe, E.S. The histological classification of diffuse large B-cell lymphomas. Semin. Hematol. 2015, 52, 57–66. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Swerdlow, S.H.; Campo, E.; Pileri, S.A.; Harris, N.L.; Stein, H.; Siebert, R.; Advani, R.; Ghielmini, M.; Salles, G.A.; Zelenetz, A.D.; et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016, 127, 2375–2390. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Li, S.; Young, K.H.; Medeiros, L.J. Diffuse large B-cell lymphoma. Pathology 2018, 50, 74–87. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. SHCE, S. WHO Classification of Tumours and Haematopoietic and Lymphoid Tissues; Harris, N.L.P.S., Stein, H., Thiele, J., Vardiman, J.W., Eds.; IARC: Lyon, France, 2008. [Google Scholar]
  5. Martelli, M.; Ferreri, A.J.; Agostinelli, C.; Di Rocco, A.; Pfreundschuh, M.; Pileri, S.A. Diffuse large B-cell lymphoma. Crit. Rev. Oncol. Hematol. 2013, 87, 146–171. [Google Scholar] [CrossRef]
  6. Grimm, K.E.; O’Malley, D.P. Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues. Ann. Diagn. Pathol. 2019, 38, 6–10. [Google Scholar] [CrossRef]
  7. Megahed, N.A.; Kohno, K.; Sakakibara, A.; Eladl, A.E.; Elsayed, A.A.; Wu, C.C.; Suzuki, Y.; Takahara, T.; Kato, S.; Nakamura, S.; et al. Anaplastic variant of diffuse large B-cell lymphoma: Reappraisal as a nodal disease with sinusoidal involvement. Pathol. Int. 2019, 69, 697–705. [Google Scholar] [CrossRef]
  8. Rosenwald, A.; Wright, G.; Chan, W.C.; Connors, J.M.; Campo, E.; Fisher, R.I.; Gascoyne, R.D.; Muller-Hermelink, H.K.; Smeland, E.B.; Giltnane, J.M.; et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002, 346, 1937–1947. [Google Scholar] [CrossRef] [PubMed]
  9. Alizadeh, A.A.; Eisen, M.B.; Davis, R.E.; Ma, C.; Lossos, I.S.; Rosenwald, A.; Boldrick, J.C.; Sabet, H.; Tran, T.; Yu, X.; et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403, 503–511. [Google Scholar] [CrossRef]
  10. Onaindia, A.; Medeiros, L.J.; Patel, K.P. Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. Mod. Pathol. 2017, 30, 1338–1366. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Dalla-Favera, R. Molecular genetics of aggressive B-cell lymphoma. Hematol. Oncol. 2017, 35 (Suppl. 1), 76–79. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Ngo, V.N.; Young, R.M.; Schmitz, R.; Jhavar, S.; Xiao, W.; Lim, K.H.; Kohlhammer, H.; Xu, W.; Yang, Y.; Zhao, H.; et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011, 470, 115–119. [Google Scholar] [CrossRef] [Green Version]
  13. Morin, R.D.; Mendez-Lago, M.; Mungall, A.J.; Goya, R.; Mungall, K.L.; Corbett, R.D.; Johnson, N.A.; Severson, T.M.; Chiu, R.; Field, M.; et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 476, 298–303. [Google Scholar] [CrossRef]
  14. Morin, R.D.; Mungall, K.; Pleasance, E.; Mungall, A.J.; Goya, R.; Huff, R.D.; Scott, D.W.; Ding, J.; Roth, A.; Chiu, R.; et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood 2013, 122, 1256–1265. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Pasqualucci, L.; Dominguez-Sola, D.; Chiarenza, A.; Fabbri, G.; Grunn, A.; Trifonov, V.; Kasper, L.H.; Lerach, S.; Tang, H.; Ma, J.; et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011, 471, 189–195. [Google Scholar] [CrossRef] [Green Version]
  16. Karube, K.; Enjuanes, A.; Dlouhy, I.; Jares, P.; Martin-Garcia, D.; Nadeu, F.; Ordóñez, G.R.; Rovira, J.; Clot, G.; Royo, C.; et al. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. Leukemia 2018, 32, 675–684. [Google Scholar] [CrossRef] [PubMed]
  17. Schmitz, R.; Wright, G.W.; Huang, D.W.; Johnson, C.A.; Phelan, J.D.; Wang, J.Q.; Roulland, S.; Kasbekar, M.; Young, R.M.; Shaffer, A.L.; et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2018, 378, 1396–1407. [Google Scholar] [CrossRef]
  18. Wright, G.W.; Huang, D.W.; Phelan, J.D.; Coulibaly, Z.A.; Roulland, S.; Young, R.M.; Wang, J.Q.; Schmitz, R.; Morin, R.D.; Tang, J.; et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell 2020, 37, 551–568.e14. [Google Scholar] [CrossRef] [PubMed]
  19. Reddy, A.; Zhang, J.; Davis, N.S.; Moffitt, A.B.; Love, C.L.; Waldrop, A.; Leppa, S.; Pasanen, A.; Meriranta, L.; Karjalainen-Lindsberg, M.L.; et al. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell 2017, 171, 481–494.e15. [Google Scholar] [CrossRef] [Green Version]
  20. Chapuy, B.; Stewart, C.; Dunford, A.J.; Kim, J.; Kamburov, A.; Redd, R.A.; Lawrence, M.S.; Roemer, M.G.M.; Li, A.J.; Ziepert, M.; et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 2018, 24, 679–690. [Google Scholar] [CrossRef]
  21. Shustik, J.; Han, G.; Farinha, P.; Johnson, N.A.; Ben Neriah, S.; Connors, J.M.; Sehn, L.H.; Horsman, D.E.; Gascoyne, R.D.; Steidl, C. Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. Haematologica 2010, 95, 96–101. [Google Scholar] [CrossRef]
  22. Ye, Q.; Xu-Monette, Z.Y.; Tzankov, A.; Deng, L.; Wang, X.; Manyam, G.C.; Visco, C.; Montes-Moreno, S.; Zhang, L.; Dybkær, K.; et al. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget 2016, 7, 2401–2416. [Google Scholar] [CrossRef] [Green Version]
  23. Li, S.; Weiss, V.L.; Wang, X.J.; Desai, P.A.; Hu, S.; Yin, C.C.; Tang, G.; Reddy, N.M.; Medeiros, L.J.; Lin, P. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis. Am. J. Surg. Pathol. 2016, 40, 253–261. [Google Scholar] [CrossRef] [PubMed]
  24. Pedersen, M.; Gang, A.O.; Poulsen, T.S.; Knudsen, H.; Lauritzen, A.F.; Nielsen, S.L.; Klausen, T.W.; Nørgaard, P. MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations. Eur. J. Haematol. 2014, 92, 42–48. [Google Scholar] [CrossRef] [PubMed]
  25. Aukema, S.M.; Kreuz, M.; Kohler, C.W.; Rosolowski, M.; Hasenclever, D.; Hummel, M.; Küppers, R.; Lenze, D.; Ott, G.; Pott, C.; et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica 2014, 99, 726–735. [Google Scholar] [CrossRef]
  26. Scott, D.W.; Wright, G.W.; Williams, P.M.; Lih, C.J.; Walsh, W.; Jaffe, E.S.; Rosenwald, A.; Campo, E.; Chan, W.C.; Connors, J.M.; et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 2014, 123, 1214–1217. [Google Scholar] [CrossRef] [PubMed]
  27. Rimsza, L.M.; Wright, G.; Schwartz, M.; Chan, W.C.; Jaffe, E.S.; Gascoyne, R.D.; Campo, E.; Rosenwald, A.; Ott, G.; Cook, J.R.; et al. Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues. Clin. Cancer Res. 2011, 17, 3727–3732. [Google Scholar] [CrossRef] [Green Version]
  28. Hans, C.P.; Weisenburger, D.D.; Greiner, T.C.; Gascoyne, R.D.; Delabie, J.; Ott, G.; Müller-Hermelink, H.K.; Campo, E.; Braziel, R.M.; Jaffe, E.S.; et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103, 275–282. [Google Scholar] [CrossRef]
  29. Pongpruttipan, T.; Sukpanichnant, S.; Assanasen, T.; Wannakrairot, P.; Boonsakan, P.; Kanoksil, W.; Kayasut, K.; Mitarnun, W.; Khuhapinant, A.; Bunworasate, U.; et al. Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and αβ, γδ, and αβ/γδ T-cell origin: A comprehensive clinicopathologic and phenotypic study. Am. J. Surg. Pathol. 2012, 36, 481–499. [Google Scholar] [CrossRef]
  30. Meyer, P.N.; Fu, K.; Greiner, T.C.; Smith, L.M.; Delabie, J.; Gascoyne, R.D.; Ott, G.; Rosenwald, A.; Braziel, R.M.; Campo, E.; et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J. Clin. Oncol. 2011, 29, 200–207. [Google Scholar] [CrossRef] [Green Version]
  31. Visco, C.; Li, Y.; Xu-Monette, Z.Y.; Miranda, R.N.; Green, T.M.; Tzankov, A.; Wen, W.; Liu, W.M.; Kahl, B.S.; d’Amore, E.S.; et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 2012, 26, 2103–2113. [Google Scholar]
  32. Yoon, N.; Ahn, S.; Yong Yoo, H.; Jin Kim, S.; Seog Kim, W.; Hyeh Ko, Y. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: Better prognostic indicator than Hans algorithm. Oncotarget 2017, 8, 22014–22022. [Google Scholar] [CrossRef] [Green Version]
  33. Hu, S.; Xu-Monette, Z.Y.; Balasubramanyam, A.; Manyam, G.C.; Visco, C.; Tzankov, A.; Liu, W.M.; Miranda, R.N.; Zhang, L.; Montes-Moreno, S.; et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: A report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2013, 121, 2715–2724. [Google Scholar] [CrossRef]
  34. Gong, Q.X.; Wang, Z.; Liu, C.; Li, X.; Lu, T.X.; Liang, J.H.; Xu, W.; Li, J.Y.; Zhang, Z.H. CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma. J. Clin. Pathol. 2018, 71, 795–801. [Google Scholar] [CrossRef]
  35. Xu-Monette, Z.Y.; Tu, M.; Jabbar, K.J.; Cao, X.; Tzankov, A.; Visco, C.; Nagarajan, L.; Cai, Q.; Montes-Moreno, S.; An, Y.; et al. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget 2015, 6, 5615–5633. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Georgiou, K.; Chen, L.; Berglund, M.; Ren, W.; de Miranda, N.F.; Lisboa, S.; Fangazio, M.; Zhu, S.; Hou, Y.; Wu, K.; et al. Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. Blood 2016, 127, 3026–3034. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Xu-Monette, Z.Y.; Wu, L.; Visco, C.; Tai, Y.C.; Tzankov, A.; Liu, W.M.; Montes-Moreno, S.; Dybkaer, K.; Chiu, A.; Orazi, A.; et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: Report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2012, 120, 3986–3996. [Google Scholar] [CrossRef] [PubMed]
  38. Ott, G. Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: Refinements of the classification, new entities and genetic findings. Br. J. Haematol. 2017, 178, 871–887. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  39. Horn, H.; Staiger, A.M.; Vöhringer, M.; Hay, U.; Campo, E.; Rosenwald, A.; Ott, G.; Ott, M.M. Diffuse large B-cell lymphomas of immunoblastic type are a major reservoir for MYC-IGH translocations. Am. J. Surg. Pathol. 2015, 39, 61–66. [Google Scholar] [CrossRef]
  40. Li, M.; Liu, Y.; Wang, Y.; Chen, G.; Chen, Q.; Xiao, H.; Liu, F.; Qi, C.; Yu, Z.; Li, X.; et al. Anaplastic Variant of Diffuse Large B-cell Lymphoma Displays Intricate Genetic Alterations and Distinct Biological Features. Am. J. Surg. Pathol. 2017, 41, 1322–1332. [Google Scholar] [CrossRef]
  41. Scott, D.W.; King, R.L.; Staiger, A.M.; Ben-Neriah, S.; Jiang, A.; Horn, H.; Mottok, A.; Farinha, P.; Slack, G.W.; Ennishi, D.; et al. High-grade B-cell lymphoma with. Blood 2018, 131, 2060–2064. [Google Scholar] [CrossRef]
  42. Ok, C.Y.; Medeiros, L.J. High-grade B-cell lymphoma: A term re-purposed in the revised WHO classification. Pathology 2020, 52, 68–77. [Google Scholar] [CrossRef] [Green Version]
  43. Wang, W.; Hu, S.; Lu, X.; Young, K.H.; Medeiros, L.J. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases. Am. J. Surg. Pathol. 2015, 39, 1132–1139. [Google Scholar] [CrossRef]
  44. Huang, W.; Medeiros, L.J.; Lin, P.; Wang, W.; Tang, G.; Khoury, J.; Konoplev, S.; Yin, C.C.; Xu, J.; Oki, Y.; et al. MYC/BCL2/BCL6 triple hit lymphoma: A study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas. Mod. Pathol. 2018, 31, 1470–1478. [Google Scholar] [CrossRef] [Green Version]
  45. Oki, Y.; Noorani, M.; Lin, P.; Davis, R.E.; Neelapu, S.S.; Ma, L.; Ahmed, M.; Rodriguez, M.A.; Hagemeister, F.B.; Fowler, N.; et al. Double hit lymphoma: The MD Anderson Cancer Center clinical experience. Br. J. Haematol. 2014, 166, 891–901. [Google Scholar] [CrossRef] [PubMed]
  46. Petrich, A.M.; Gandhi, M.; Jovanovic, B.; Castillo, J.J.; Rajguru, S.; Yang, D.T.; Shah, K.A.; Whyman, J.D.; Lansigan, F.; Hernandez-Ilizaliturri, F.J.; et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: A multicenter retrospective analysis. Blood 2014, 124, 2354–2361. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Niitsu, N.; Okamoto, M.; Miura, I.; Hirano, M. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 2009, 23, 777–783. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Johnson, N.A.; Slack, G.W.; Savage, K.J.; Connors, J.M.; Ben-Neriah, S.; Rogic, S.; Scott, D.W.; Tan, K.L.; Steidl, C.; Sehn, L.H.; et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol. 2012, 30, 3452–3459. [Google Scholar] [CrossRef]
  49. Pillai, R.K.; Sathanoori, M.; Van Oss, S.B.; Swerdlow, S.H. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas. Am. J. Surg. Pathol. 2013, 37, 323–332. [Google Scholar] [CrossRef]
  50. Li, S.; Saksena, A.; Desai, P.; Xu, J.; Zuo, Z.; Lin, P.; Tang, G.; Yin, C.C.; Seegmiller, A.; Jorgensen, J.L.; et al. Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphoma. Oncotarget 2016, 7, 38122–38132. [Google Scholar] [CrossRef] [Green Version]
  51. Roth, C.G.; Gillespie-Twardy, A.; Marks, S.; Agha, M.; Raptis, A.; Hou, J.Z.; Farah, R.; Lin, Y.; Qian, Y.; Pantanowitz, L.; et al. Flow Cytometric Evaluation of Double/Triple Hit Lymphoma. Oncol. Res. 2016, 23, 137–146. [Google Scholar] [CrossRef] [PubMed]
  52. Johnson, N.A.; Savage, K.J.; Ludkovski, O.; Ben-Neriah, S.; Woods, R.; Steidl, C.; Dyer, M.J.; Siebert, R.; Kuruvilla, J.; Klasa, R.; et al. Lymphomas with concurrent BCL2 and MYC translocations: The critical factors associated with survival. Blood 2009, 114, 2273–2279. [Google Scholar] [CrossRef] [Green Version]
  53. Pedersen, M.; Gang, A.O.; Poulsen, T.S.; Knudsen, H.; Lauritzen, A.F.; Nielsen, S.L.; Gang, U.O.; Nørgaard, P. Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma—A single centre’s experience. Eur. J. Haematol. 2012, 89, 63–71. [Google Scholar] [CrossRef]
  54. McPhail, E.D.; Maurer, M.J.; Macon, W.R.; Feldman, A.L.; Kurtin, P.J.; Ketterling, R.P.; Vaidya, R.; Cerhan, J.R.; Ansell, S.M.; Porrata, L.F.; et al. Inferior survival in high-grade B-cell lymphoma with. Haematologica 2018, 103, 1899–1907. [Google Scholar] [CrossRef] [Green Version]
  55. Rosenwald, A.; Bens, S.; Advani, R.; Barrans, S.; Copie-Bergman, C.; Elsensohn, M.H.; Natkunam, Y.; Calaminici, M.; Sander, B.; Baia, M.; et al. Prognostic Significance of. J. Clin. Oncol. 2019, 37, 3359–3368. [Google Scholar] [CrossRef] [Green Version]
  56. King, R.L.; McPhail, E.D.; Meyer, R.G.; Vasmatzis, G.; Pearce, K.; Smadbeck, J.B.; Ketterling, R.P.; Smoley, S.A.; Greipp, P.T.; Hoppman, N.L.; et al. False-negative rates for. Haematologica 2019, 104, e248–e251. [Google Scholar] [CrossRef] [Green Version]
  57. Boerma, E.G.; Siebert, R.; Kluin, P.M.; Baudis, M. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: A historical review of cytogenetics in the light of todays knowledge. Leukemia 2009, 23, 225–234. [Google Scholar] [CrossRef] [Green Version]
  58. Momose, S.; Weißbach, S.; Pischimarov, J.; Nedeva, T.; Bach, E.; Rudelius, M.; Geissinger, E.; Staiger, A.M.; Ott, G.; Rosenwald, A. The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum. Leukemia 2015, 29, 1789–1791. [Google Scholar] [CrossRef] [PubMed]
  59. Evrard, S.M.; Péricart, S.; Grand, D.; Amara, N.; Escudié, F.; Gilhodes, J.; Bories, P.; Traverse-Glehen, A.; Dubois, R.; Brousset, P.; et al. Targeted next generation sequencing reveals high mutation frequency of. Haematologica 2019, 104, e154–e157. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  60. Stengel, A.; Kern, W.; Meggendorfer, M.; Haferlach, T.; Haferlach, C. Detailed molecular analysis and evaluation of prognosis in cases with high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. Br. J. Haematol. 2019, 185, 951–954. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  61. Kanagal-Shamanna, R.; Medeiros, L.J.; Lu, G.; Wang, S.A.; Manning, J.T.; Lin, P.; Penn, G.M.; Young, K.H.; You, M.J.; Vega, F.; et al. High-grade B cell lymphoma, unclassifiable, with blastoid features: An unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis. Histopathology 2012, 61, 945–954. [Google Scholar] [CrossRef] [PubMed]
  62. Moore, E.M.; Aggarwal, N.; Surti, U.; Swerdlow, S.H. Further Exploration of the Complexities of Large B-Cell Lymphomas With MYC Abnormalities and the Importance of a Blastoid Morphology. Am. J. Surg. Pathol. 2017, 41, 1155–1166. [Google Scholar] [CrossRef] [PubMed]
  63. Landsburg, D.J.; Falkiewicz, M.K.; Petrich, A.M.; Chu, B.A.; Behdad, A.; Li, S.; Medeiros, L.J.; Cassaday, R.D.; Reddy, N.M.; Bast, M.A.; et al. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. Br. J. Haematol. 2016, 175, 631–640. [Google Scholar] [CrossRef] [Green Version]
  64. Li, S.; Lin, P.; Young, K.H.; Kanagal-Shamanna, R.; Yin, C.C.; Medeiros, L.J. MYC/BCL2 double-hit high-grade B-cell lymphoma. Adv. Anat. Pathol. 2013, 20, 315–326. [Google Scholar] [CrossRef] [PubMed]
  65. Casulo, C.; Friedberg, J.W. Burkitt lymphoma- a rare but challenging lymphoma. Best Pr. Res. Clin. Haematol. 2018, 31, 279–284. [Google Scholar] [CrossRef] [PubMed]
  66. Orem, J.; Mbidde, E.K.; Lambert, B.; de Sanjose, S.; Weiderpass, E. Burkitt’s lymphoma in Africa, a review of the epidemiology and etiology. Afr. Health Sci. 2007, 7, 166–175. [Google Scholar] [PubMed]
  67. Kelly, G.L.; Rickinson, A.B. Burkitt lymphoma: Revisiting the pathogenesis of a virus-associated malignancy. Hematol. Am. Soc. Hematol. Educ. Program 2007, 277–284. [Google Scholar] [CrossRef] [Green Version]
  68. Ribrag, V.; Koscielny, S.; Bosq, J.; Leguay, T.; Casasnovas, O.; Fornecker, L.M.; Recher, C.; Ghesquieres, H.; Morschhauser, F.; Girault, S.; et al. Rituximab and dose-dense chemotherapy for adults with Burkitt’s lymphoma: A randomised, controlled, open-label, phase 3 trial. Lancet 2016, 387, 2402–2411. [Google Scholar] [CrossRef]
  69. Velavan, T.P. Epstein-Barr virus, malaria and endemic Burkitt lymphoma. EBioMedicine 2019, 39, 13–14. [Google Scholar] [CrossRef] [Green Version]
  70. Queiroga, E.M.; Gualco, G.; Weiss, L.M.; Dittmer, D.P.; Araujo, I.; Klumb, C.E.; Harrington, W.J.; Bacchi, C.E. Burkitt lymphoma in Brazil is characterized by geographically distinct clinicopathologic features. Am. J. Clin. Pathol. 2008, 130, 946–956. [Google Scholar] [CrossRef] [Green Version]
  71. Araujo, I.; Bittencourt, A.L.; Barbosa, H.S.; Netto, E.M.; Mendonça, N.; Foss, H.D.; Hummel, M.; Stein, H. The high frequency of EBV infection in pediatric Hodgkin lymphoma is related to the classical type in Bahia, Brazil. Virchows Arch. 2006, 449, 315–319. [Google Scholar] [CrossRef] [PubMed]
  72. Hassan, R.; Klumb, C.E.; Felisbino, F.E.; Guiretti, D.M.; White, L.R.; Stefanoff, C.G.; Barros, M.H.; Seuánez, H.N.; Zalcberg, I.R. Clinical and demographic characteristics of Epstein-Barr virus-associated childhood Burkitt’s lymphoma in Southeastern Brazil: Epidemiological insights from an intermediate risk region. Haematologica 2008, 93, 780–783. [Google Scholar] [CrossRef]
  73. Penther, D.; Viailly, P.J.; Latour, S.; Etancelin, P.; Bohers, E.; Vellemans, H.; Camus, V.; Menard, A.L.; Coutant, S.; Lanic, H.; et al. A recurrent clonally distinct Burkitt lymphoma case highlights genetic key events contributing to oncogenesis. Genes Chromosomes Cancer 2019, 58, 595–601. [Google Scholar] [CrossRef] [PubMed]
  74. Dunleavy, K.; Little, R.F.; Wilson, W.H. Update on Burkitt Lymphoma. Hematol. Oncol. Clin. North. Am. 2016, 30, 1333–1343. [Google Scholar] [CrossRef]
  75. Schmitz, R.; Young, R.M.; Ceribelli, M.; Jhavar, S.; Xiao, W.; Zhang, M.; Wright, G.; Shaffer, A.L.; Hodson, D.J.; Buras, E.; et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012, 490, 116–120. [Google Scholar] [CrossRef] [PubMed]
  76. Love, C.; Sun, Z.; Jima, D.; Li, G.; Zhang, J.; Miles, R.; Richards, K.L.; Dunphy, C.H.; Choi, W.W.; Srivastava, G.; et al. The genetic landscape of mutations in Burkitt lymphoma. Nat. Genet. 2012, 44, 1321–1325. [Google Scholar] [CrossRef] [Green Version]
  77. Panea, R.I.; Love, C.L.; Shingleton, J.R.; Reddy, A.; Bailey, J.A.; Moormann, A.M.; Otieno, J.A.; Ong’echa, J.M.; Oduor, C.I.; Schroeder, K.M.S.; et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood 2019, 134, 1598–1607. [Google Scholar] [CrossRef] [PubMed]
  78. Saleh, K.; Michot, J.M.; Camara-Clayette, V.; Vassetsky, Y.; Ribrag, V. Burkitt and Burkitt-Like Lymphomas: A Systematic Review. Curr. Oncol. Rep. 2020, 22, 33. [Google Scholar] [CrossRef] [PubMed]
  79. Farria, A.T.; Mustachio, L.M.; Akdemir, Z.H.C.; Dent, S.Y.R. GCN5 HAT inhibition reduces human Burkitt lymphoma cell survival through reduction of MYC target gene expression and impeding BCR signaling pathways. Oncotarget 2019, 10, 5847–5858. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  80. Hemann, M.T.; Bric, A.; Teruya-Feldstein, J.; Herbst, A.; Nilsson, J.A.; Cordon-Cardo, C.; Cleveland, J.L.; Tansey, W.P.; Lowe, S.W. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005, 436, 807–811. [Google Scholar] [CrossRef] [Green Version]
  81. Hüllein, J.; Słabicki, M.; Rosolowski, M.; Jethwa, A.; Habringer, S.; Tomska, K.; Kurilov, R.; Lu, J.; Scheinost, S.; Wagener, R.; et al. MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma. Cancer Res. 2019, 79, 3125–3138. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  82. Rosenthal, A.; Rimsza, L. Genomics of aggressive B-cell lymphoma. Hematol. Am. Soc. Hematol. Educ. Program 2018, 2018, 69–74. [Google Scholar] [CrossRef] [Green Version]
  83. Gonzalez-Farre, B.; Ramis-Zaldivar, J.E.; Salmeron-Villalobos, J.; Balagué, O.; Celis, V.; Verdu-Amoros, J.; Nadeu, F.; Sábado, C.; Ferrández, A.; Garrido, M.; et al. Burkitt-like lymphoma with 11q aberration: A germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma. Haematologica 2019, 104, 1822–1829. [Google Scholar] [CrossRef] [PubMed]
  84. Grygalewicz, B.; Woroniecka, R.; Rymkiewicz, G.; Rygier, J.; Borkowska, K.; Kotyl, A.; Blachnio, K.; Bystydzienski, Z.; Nowakowska, B.; Pienkowska-Grela, B. The 11q-Gain/Loss Aberration Occurs Recurrently in MYC-Negative Burkitt-like Lymphoma With 11q Aberration, as Well as MYC-Positive Burkitt Lymphoma and MYC-Positive High-Grade B-Cell Lymphoma, NOS. Am. J. Clin. Pathol. 2017, 149, 17–28. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  85. Collins, K.; Mnayer, L.; Shen, P. Burkitt-like lymphoma with 11q aberration. Clin. Case Rep. 2019, 7, 1823–1824. [Google Scholar] [CrossRef] [Green Version]
  86. Salaverria, I.; Martin-Guerrero, I.; Wagener, R.; Kreuz, M.; Kohler, C.W.; Richter, J.; Pienkowska-Grela, B.; Adam, P.; Burkhardt, B.; Claviez, A.; et al. A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood 2014, 123, 1187–1198. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  87. Rymkiewicz, G.; Grygalewicz, B.; Chechlinska, M.; Blachnio, K.; Bystydzienski, Z.; Romejko-Jarosinska, J.; Woroniecka, R.; Zajdel, M.; Domanska-Czyz, K.; Martin-Garcia, D.; et al. A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration. Mod. Pathol. 2018, 31, 732–743. [Google Scholar] [CrossRef]
  88. Liu, Y.; Bian, T.; Zhang, Y.; Zheng, Y.; Zhang, J.; Zhou, X.; Xie, J. A combination of LMO2 negative and CD38 positive is useful for the diagnosis of Burkitt lymphoma. Diagn. Pathol. 2019, 14, 100. [Google Scholar] [CrossRef] [Green Version]
  89. Richter, J.; Schlesner, M.; Hoffmann, S.; Kreuz, M.; Leich, E.; Burkhardt, B.; Rosolowski, M.; Ammerpohl, O.; Wagener, R.; Bernhart, S.H.; et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat. Genet. 2012, 44, 1316–1320. [Google Scholar]
  90. Wagener, R.; Seufert, J.; Raimondi, F.; Bens, S.; Kleinheinz, K.; Nagel, I.; Altmüller, J.; Thiele, H.; Hübschmann, D.; Kohler, C.W.; et al. The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma. Blood 2019, 133, 962–966. [Google Scholar] [CrossRef] [Green Version]
  91. Hartmann, S.; Plütschow, A.; Mottok, A.; Bernd, H.W.; Feller, A.C.; Ott, G.; Cogliatti, S.; Fend, F.; Quintanilla-Martinez, L.; Stein, H.; et al. The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma. Am. J. Hematol. 2019, 94, 1208–1213. [Google Scholar] [CrossRef]
  92. Nam-Cha, S.H.; Roncador, G.; Sanchez-Verde, L.; Montes-Moreno, S.; Acevedo, A.; Domínguez-Franjo, P.; Piris, M.A. PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma. Am. J. Surg. Pathol. 2008, 32, 1252–1257. [Google Scholar] [CrossRef]
  93. Nam-Cha, S.H.; Montes-Moreno, S.; Salcedo, M.T.; Sanjuan, J.; Garcia, J.F.; Piris, M.A. Lymphocyte-rich classical Hodgkin’s lymphoma: Distinctive tumor and microenvironment markers. Mod. Pathol. 2009, 22, 1006–1015. [Google Scholar] [CrossRef] [Green Version]
  94. Hartmann, S.; Döring, C.; Jakobus, C.; Rengstl, B.; Newrzela, S.; Tousseyn, T.; Sagaert, X.; Ponzoni, M.; Facchetti, F.; de Wolf-Peeters, C.; et al. Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma—Endpoints of a spectrum of one disease? PLoS ONE 2013, 8, e78812. [Google Scholar] [CrossRef] [PubMed]
  95. Brune, V.; Tiacci, E.; Pfeil, I.; Döring, C.; Eckerle, S.; van Noesel, C.J.; Klapper, W.; Falini, B.; von Heydebreck, A.; Metzler, D.; et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J. Exp. Med. 2008, 205, 2251–2268. [Google Scholar] [CrossRef] [PubMed]
  96. Wickert, R.S.; Weisenburger, D.D.; Tierens, A.; Greiner, T.C.; Chan, W.C. Clonal relationship between lymphocytic predominance Hodgkin’s disease and concurrent or subsequent large-cell lymphoma of B lineage. Blood 1995, 86, 2312–2320. [Google Scholar] [CrossRef]
  97. Greiner, T.C.; Gascoyne, R.D.; Anderson, M.E.; Kingma, D.W.; Adomat, S.A.; Said, J.; Jaffe, E.S. Nodular lymphocyte-predominant Hodgkin’s disease associated with large-cell lymphoma: Analysis of Ig gene rearrangements by V-J polymerase chain reaction. Blood 1996, 88, 657–666. [Google Scholar] [CrossRef]
  98. Ohno, T.; Huang, J.Z.; Wu, G.; Park, K.H.; Weisenburger, D.D.; Chan, W.C. The tumor cells in nodular lymphocyte-predominant Hodgkin disease are clonally related to the large cell lymphoma occurring in the same individual. Direct demonstration by single cell analysis. Am. J. Clin. Pathol. 2001, 116, 506–511. [Google Scholar] [CrossRef] [Green Version]
  99. Al-Mansour, M.; Connors, J.M.; Gascoyne, R.D.; Skinnider, B.; Savage, K.J. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin’s lymphoma. J. Clin. Oncol. 2010, 28, 793–799. [Google Scholar] [CrossRef] [PubMed]
  100. Farrell, K.; McKay, P.; Leach, M. Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: Evidence from 14-year follow-up in the West of Scotland Cancer Network. Leuk. Lymphoma 2011, 52, 1920–1928. [Google Scholar] [CrossRef]
  101. Fan, Z.; Natkunam, Y.; Bair, E.; Tibshirani, R.; Warnke, R.A. Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am. J. Surg. Pathol. 2003, 27, 1346–1356. [Google Scholar] [CrossRef]
  102. Hartmann, S.; Eichenauer, D.A.; Plütschow, A.; Mottok, A.; Bob, R.; Koch, K.; Bernd, H.W.; Cogliatti, S.; Hummel, M.; Feller, A.C.; et al. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group(GHSG). Blood 2013, 122, 4246–4252. [Google Scholar] [CrossRef] [Green Version]
  103. Hartmann, S.; Döring, C.; Vucic, E.; Chan, F.C.; Ennishi, D.; Tousseyn, T.; de Wolf-Peeters, C.; Perner, S.; Wlodarska, I.; Steidl, C.; et al. Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma. Br. J. Haematol. 2015, 169, 415–422. [Google Scholar] [CrossRef]
  104. Franke, S.; Wlodarska, I.; Maes, B.; Vandenberghe, P.; Achten, R.; Hagemeijer, A.; De Wolf-Peeters, C. Comparative genomic hybridization pattern distinguishes T-cell/histiocyte-rich B-cell lymphoma from nodular lymphocyte predominance Hodgkin’s lymphoma. Am. J. Pathol. 2002, 161, 1861–1867. [Google Scholar] [CrossRef]
  105. Poppe, B.; De Paepe, P.; Michaux, L.; Dastugue, N.; Bastard, C.; Herens, C.; Moreau, E.; Cavazzini, F.; Yigit, N.; Van Limbergen, H.; et al. PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements. Genes Chromosomes Cancer 2005, 44, 218–223. [Google Scholar] [CrossRef]
  106. Renné, C.; Martín-Subero, J.I.; Hansmann, M.L.; Siebert, R. Molecular cytogenetic analyses of immunoglobulin loci in nodular lymphocyte predominant Hodgkin’s lymphoma reveal a recurrent IGH-BCL6 juxtaposition. J. Mol. Diagn. 2005, 7, 352–356. [Google Scholar] [CrossRef]
  107. Hartmann, S.; Schuhmacher, B.; Rausch, T.; Fuller, L.; Döring, C.; Weniger, M.; Lollies, A.; Weiser, C.; Thurner, L.; Rengstl, B.; et al. Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma. Leukemia 2016, 30, 844–853. [Google Scholar] [CrossRef]
  108. Schuhmacher, B.; Bein, J.; Rausch, T.; Benes, V.; Tousseyn, T.; Vornanen, M.; Ponzoni, M.; Thurner, L.; Gascoyne, R.; Steidl, C.; et al. JUNB, DUSP2, SGK1, SOCS1 and CREBBP are frequently mutated in T-cell/histiocyte-rich large B-cell lymphoma. Haematologica 2019, 104, 330–337. [Google Scholar]
  109. Tian, X.; Pelton, A.; Shahsafaei, A.; Dorfman, D.M. Differential expression of enhancer of zeste homolog 2(EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas. Mod. Pathol. 2016, 29, 1050–1057. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  110. Tian, X.; Xu, J.; Dorfman, D.M. Utility of Combined EZH2, p-ERK1/2, p-STAT, and MYC Expression in the Differential Diagnosis of EZH2-positive Hodgkin Lymphomas and Related Large B-Cell Lymphomas. Am. J. Surg. Pathol. 2019, 43, 102–109. [Google Scholar] [CrossRef]
  111. Churchill, H.R.; Roncador, G.; Warnke, R.A.; Natkunam, Y. Programmed death 1 expression in variant immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma: Comparison with CD57 and lymphomas in the differential diagnosis. Hum. Pathol. 2010, 41, 1726–1734. [Google Scholar] [CrossRef] [PubMed]
  112. Visser, L.; Rutgers, B.; Diepstra, A.; van den Berg, A.; Sattarzadeh, A. Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma. Int. J. Mol. Sci. 2016, 17, 2127. [Google Scholar]
  113. Van Loo, P.; Tousseyn, T.; Vanhentenrijk, V.; Dierickx, D.; Malecka, A.; Vanden Bempt, I.; Verhoef, G.; Delabie, J.; Marynen, P.; Matthys, P.; et al. T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response. Haematologica 2010, 95, 440–448. [Google Scholar] [CrossRef] [Green Version]
  114. Griffin, G.K.; Weirather, J.L.; Roemer, M.; Lipschitz, M.; Kelley, A.; Chen, P.H.; Gusenleitner, D.; Jeter, E.; Gjini, E.; Chapuy, B.; et al. Spatial Signatures Identify Immune Escape via PD-1 as a Defining Feature of T-cell/Histiocyte-rich Large B-cell Lymphoma. Blood 2021, 137, 1353–1364. [Google Scholar] [CrossRef]
  115. Randall, C.; Fedoriw, Y. Pathology and diagnosis of follicular lymphoma and related entities. Pathology 2020, 52, 30–39. [Google Scholar] [CrossRef] [PubMed]
  116. Salaverria, I.; Philipp, C.; Oschlies, I.; Kohler, C.W.; Kreuz, M.; Szczepanowski, M.; Burkhardt, B.; Trautmann, H.; Gesk, S.; Andrusiewicz, M.; et al. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood 2011, 118, 139–147. [Google Scholar] [CrossRef]
  117. Yu, Y.T.; Sakata, S.; Takeuchi, K.; Medeiros, L.J.; Chang, K.C. Tonsillar follicular large B-cell lymphoma with. J. Clin. Pathol. 2020, 73, 120. [Google Scholar] [CrossRef] [PubMed]
  118. Chisholm, K.M.; Mohlman, J.; Liew, M.; Termuhlen, A.; Cairo, M.S.; Gross, T.G.; Perkins, S.L.; Miles, R.R. IRF4 translocation status in pediatric follicular and diffuse large B-cell lymphoma patients enrolled in Children’s Oncology Group trials. Pediatr. Blood Cancer 2019, 66, e27770. [Google Scholar] [CrossRef]
  119. Woessmann, W.; Quintanilla-Martinez, L. Rare mature B-cell lymphomas in children and adolescents. Hematol. Oncol. 2019, 37 (Suppl. 1), 53–61. [Google Scholar] [CrossRef] [Green Version]
  120. Quintanilla-Martinez, L. The 2016 updated WHO classification of lymphoid neoplasias. Hematol. Oncol. 2017, 35 (Suppl. 1), 37–45. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  121. Quintanilla-Martinez, L.; Sander, B.; Chan, J.K.; Xerri, L.; Ott, G.; Campo, E.; Swerdlow, S.H. Indolent lymphomas in the pediatric population: Follicular lymphoma, IRF4/MUM1+ lymphoma, nodal marginal zone lymphoma and chronic lymphocytic leukemia. Virchows Arch. 2016, 468, 141–157. [Google Scholar] [CrossRef]
  122. Chen, L.; Al-Kzayer, L.F.; Liu, T.; Kobayashi, N.; Nakazawa, Y.; Koike, K. IFR4/MUM1-positive lymphoma in Waldeyer ring with co-expression of CD5 and CD10. Pediatr. Blood Cancer 2017, 64, 311–314. [Google Scholar] [CrossRef]
  123. Montes-Moreno, S.; King, R.L.; Oschlies, I.; Ponzoni, M.; Goodlad, J.R.; Dotlic, S.; Traverse-Glehen, A.; Ott, G.; Ferry, J.A.; Calaminici, M. Update on lymphoproliferative disorders of the gastrointestinal tract: Disease spectrum from indolent lymphoproliferations to aggressive lymphomas. Virchows Arch. 2020, 476, 667–681. [Google Scholar] [CrossRef]
  124. Jaffe, E.S. Diagnosis and classification of lymphoma: Impact of technical advances. Semin. Hematol. 2019, 56, 30–36. [Google Scholar] [CrossRef] [PubMed]
  125. Au-Yeung, R.K.H.; Arias Padilla, L.; Zimmermann, M.; Oschlies, I.; Siebert, R.; Woessmann, W.; Burkhardt, B.; Klapper, W. Experience with provisional WHO-entities large B-cell lymphoma with IRF4-rearrangement and Burkitt-like lymphoma with 11q aberration in paediatric patients of the NHL-BFM group. Br. J. Haematol. 2020, 190, 753–763. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  126. Salaverria, I.; Martin-Guerrero, I.; Burkhardt, B.; Kreuz, M.; Zenz, T.; Oschlies, I.; Arnold, N.; Baudis, M.; Bens, S.; García-Orad, A.; et al. High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas. Genes Chromosomes Cancer 2013, 52, 150–155. [Google Scholar] [CrossRef] [PubMed]
  127. Ramis-Zaldivar, J.E.; Gonzalez-Farré, B.; Balagué, O.; Celis, V.; Nadeu, F.; Salmerón-Villalobos, J.; Andrés, M.; Martin-Guerrero, I.; Garrido-Pontnou, M.; Gaafar, A.; et al. Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. Blood 2020, 135, 274–286. [Google Scholar] [CrossRef]
  128. Martelli, M.; Ferreri, A.; Di Rocco, A.; Ansuinelli, M.; Johnson, P.W.M. Primary mediastinal large B-cell lymphoma. Crit. Rev. Oncol. Hematol. 2017, 113, 318–327. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  129. Bledsoe, J.R.; Redd, R.A.; Hasserjian, R.P.; Soumerai, J.D.; Nishino, H.T.; Boyer, D.F.; Ferry, J.A.; Zukerberg, L.R.; Harris, N.L.; Abramson, J.S.; et al. The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome. Am. J. Hematol. 2016, 91, E436–E441. [Google Scholar] [CrossRef]
  130. Quintanilla-Martinez, L.; Fend, F. Mediastinal gray zone lymphoma. Haematologica 2011, 96, 496–499. [Google Scholar] [CrossRef] [Green Version]
  131. Sukswai, N.; Lyapichev, K.; Khoury, J.D.; Medeiros, L.J. Diffuse large B-cell lymphoma variants: An update. Pathology 2020, 52, 53–67. [Google Scholar] [CrossRef] [Green Version]
  132. Mansouri, L.; Noerenberg, D.; Young, E.; Mylonas, E.; Abdulla, M.; Frick, M.; Asmar, F.; Ljungström, V.; Schneider, M.; Yoshida, K.; et al. Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Blood 2016, 128, 2666–2670. [Google Scholar] [CrossRef] [Green Version]
  133. Wessendorf, S.; Barth, T.F.; Viardot, A.; Mueller, A.; Kestler, H.A.; Kohlhammer, H.; Lichter, P.; Bentz, M.; Döhner, H.; Möller, P.; et al. Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: An analysis of 37 tumor samples using high-resolution genomic profiling(array-CGH). Leukemia 2007, 21, 2463–2469. [Google Scholar] [CrossRef]
  134. Jardin, F.; Pujals, A.; Pelletier, L.; Bohers, E.; Camus, V.; Mareschal, S.; Dubois, S.; Sola, B.; Ochmann, M.; Lemonnier, F.; et al. Recurrent mutations of the exportin 1 gene(XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. Am. J. Hematol. 2016, 91, 923–930. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  135. Ducharme, O.; Beylot-Barry, M.; Pham-Ledard, A.; Bohers, E.; Viailly, P.J.; Bandres, T.; Faur, N.; Frison, E.; Vergier, B.; Jardin, F.; et al. Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type. J. Investig. Derm. 2019, 139, 2334–2342.e8. [Google Scholar] [CrossRef] [PubMed]
  136. Viganò, E.; Gunawardana, J.; Mottok, A.; Van Tol, T.; Mak, K.; Chan, F.C.; Chong, L.; Chavez, E.; Woolcock, B.; Takata, K.; et al. Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation. Blood 2018, 131, 2036–2046. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  137. Mottok, A.; Woolcock, B.; Chan, F.C.; Tong, K.M.; Chong, L.; Farinha, P.; Telenius, A.; Chavez, E.; Ramchandani, S.; Drake, M.; et al. Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression. Cell Rep. 2015, 13, 1418–1431. [Google Scholar] [CrossRef] [Green Version]
  138. Mottok, A.; Hung, S.S.; Chavez, E.A.; Woolcock, B.; Telenius, A.; Chong, L.C.; Meissner, B.; Nakamura, H.; Rushton, C.; Viganò, E.; et al. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. Blood 2019, 134, 802–813. [Google Scholar] [CrossRef]
  139. Senff, N.J.; Hoefnagel, J.J.; Jansen, P.M.; Vermeer, M.H.; van Baarlen, J.; Blokx, W.A.; Canninga-van Dijk, M.R.; Geerts, M.L.; Hebeda, K.M.; Kluin, P.M.; et al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: Comparison with previous classifications and identification of prognostic markers. J. Clin. Oncol. 2007, 25, 1581–1587. [Google Scholar] [CrossRef] [Green Version]
  140. Zinzani, P.L.; Quaglino, P.; Pimpinelli, N.; Berti, E.; Baliva, G.; Rupoli, S.; Martelli, M.; Alaibac, M.; Borroni, G.; Chimenti, S.; et al. Prognostic factors in primary cutaneous B-cell lymphoma: The Italian Study Group for Cutaneous Lymphomas. J. Clin. Oncol. 2006, 24, 1376–1382. [Google Scholar] [CrossRef] [Green Version]
  141. Hristov, A.C. Primary cutaneous diffuse large B-cell lymphoma, leg type: Diagnostic considerations. Arch. Pathol. Lab. Med. 2012, 136, 876–881. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  142. Rozati, S.; Kempf, W.; Ostheeren-Michaelis, S.; Bode-Lesniewska, B.; Zimmermann, D.R.; Dummer, R.; Cozzio, A. Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, With Bilateral Intraocular Involvement and Infiltration to the CNS. J. Clin. Oncol. 2016, 34, e93–e96. [Google Scholar] [CrossRef]
  143. Kempf, W.; Zimmermann, A.K.; Mitteldorf, C. Cutaneous lymphomas-An update 2019. Hematol. Oncol. 2019, 37 (Suppl. 1), 43–47. [Google Scholar] [CrossRef] [Green Version]
  144. Gardette, E.; Maraval, A.; Brunet-Possenti, F.; Quereux, G.; Beltraminelli, H.; Templier, I.; Hodel, J.; Scherman, E.; Durot, E.; Bagot, M.; et al. Central nervous system involvement of primary cutaneous diffuse large B-cell lymphoma, leg type: 13 cases. J. Eur. Acad. Derm. Venereol. 2017, 31, e498–e501. [Google Scholar] [CrossRef] [PubMed]
  145. Grange, F.; Bekkenk, M.W.; Wechsler, J.; Meijer, C.J.; Cerroni, L.; Bernengo, M.; Bosq, J.; Hedelin, G.; Fink Puches, R.; van Vloten, W.A.; et al. Prognostic factors in primary cutaneous large B-cell lymphomas: A European multicenter study. J. Clin. Oncol. 2001, 19, 3602–3610. [Google Scholar] [CrossRef] [PubMed]
  146. Grange, F.; Joly, P.; Barbe, C.; Bagot, M.; Dalle, S.; Ingen-Housz-Oro, S.; Maubec, E.; D’Incan, M.; Ram-Wolff, C.; Dalac, S.; et al. Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France. JAMA Derm. 2014, 150, 535–541. [Google Scholar] [CrossRef] [Green Version]
  147. Hope, C.B.; Pincus, L.B. Primary cutaneous B-cell lymphomas with large cell predominance-primary cutaneous follicle center lymphoma, diffuse large B-cell lymphoma, leg type and intravascular large B-cell lymphoma. Semin. Diagn. Pathol. 2017, 34, 85–98. [Google Scholar] [CrossRef]
  148. Koens, L.; Vermeer, M.H.; Willemze, R.; Jansen, P.M. IgM expression on paraffin sections distinguishes primary cutaneous large B-cell lymphoma, leg type from primary cutaneous follicle center lymphoma. Am. J. Surg. Pathol. 2010, 34, 1043–1048. [Google Scholar] [CrossRef]
  149. Demirkesen, C.; Tüzüner, N.; Esen, T.; Lebe, B.; Ozkal, S. The expression of IgM is helpful in the differentiation of primary cutaneous diffuse large B cell lymphoma and follicle center lymphoma. Leuk. Res. 2011, 35, 1269–1272. [Google Scholar] [CrossRef] [PubMed]
  150. Kodama, K.; Massone, C.; Chott, A.; Metze, D.; Kerl, H.; Cerroni, L. Primary cutaneous large B-cell lymphomas: Clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood 2005, 106, 2491–2497. [Google Scholar] [CrossRef]
  151. Menguy, S.; Frison, E.; Prochazkova-Carlotti, M.; Dalle, S.; Dereure, O.; Boulinguez, S.; Dalac, S.; Machet, L.; Ram-Wolff, C.; Verneuil, L.; et al. Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas. Mod. Pathol. 2018, 31, 1332–1342. [Google Scholar] [CrossRef] [Green Version]
  152. Robson, A.; Shukur, Z.; Ally, M.; Kluk, J.; Liu, K.; Pincus, L.; Sahni, D.; Sundram, U.; Subtil, A.; Karai, L.; et al. Immunocytochemical p63 expression discriminates between primary cutaneous follicle centre cell and diffuse large B cell lymphoma-leg type, and is of the TAp63 isoform. Histopathology 2016, 69, 11–19. [Google Scholar] [CrossRef] [PubMed]
  153. Hallermann, C.; Kaune, K.M.; Siebert, R.; Vermeer, M.H.; Tensen, C.P.; Willemze, R.; Gunawan, B.; Bertsch, H.P.; Neumann, C. Chromosomal aberration patterns differ in subtypes of primary cutaneous B cell lymphomas. J. Investig. Derm. 2004, 122, 1495–1502. [Google Scholar] [CrossRef] [Green Version]
  154. Dijkman, R.; Tensen, C.P.; Jordanova, E.S.; Knijnenburg, J.; Hoefnagel, J.J.; Mulder, A.A.; Rosenberg, C.; Raap, A.K.; Willemze, R.; Szuhai, K.; et al. Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma. J. Clin. Oncol. 2006, 24, 296–305. [Google Scholar] [CrossRef]
  155. Menguy, S.; Prochazkova-Carlotti, M.; Beylot-Barry, M.; Saltel, F.; Vergier, B.; Merlio, J.P.; Pham-Ledard, A. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. Am. J. Surg. Pathol. 2018, 42, 326–334. [Google Scholar] [CrossRef] [PubMed]
  156. Zhou, X.A.; Louissaint, A.; Wenzel, A.; Yang, J.; Martinez-Escala, M.E.; Moy, A.P.; Morgan, E.A.; Paxton, C.N.; Hong, B.; Andersen, E.F.; et al. Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type. J. Investig. Derm. 2018, 138, 2365–2376. [Google Scholar] [CrossRef] [Green Version]
  157. Mareschal, S.; Pham-Ledard, A.; Viailly, P.J.; Dubois, S.; Bertrand, P.; Maingonnat, C.; Fontanilles, M.; Bohers, E.; Ruminy, P.; Tournier, I.; et al. Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing. J. Investig. Derm. 2017, 137, 1984–1994. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  158. Pham-Ledard, A.; Prochazkova-Carlotti, M.; Andrique, L.; Cappellen, D.; Vergier, B.; Martinez, F.; Grange, F.; Petrella, T.; Beylot-Barry, M.; Merlio, J.P. Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma. Mod. Pathol. 2014, 27, 402–411. [Google Scholar] [CrossRef]
  159. Menguy, S.; Laharanne, E.; Prochazkova-Carlotti, M.; Gros, A.; Vergier, B.; Parrens, M.; Beylot-Barry, M.; Pham-Ledard, A.; Merlio, J.P. Challenges in Assessing MYC Rearrangement in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type. Am. J. Surg. Pathol. 2020, 44, 424–427. [Google Scholar] [CrossRef] [PubMed]
  160. Pham-Ledard, A.; Cappellen, D.; Martinez, F.; Vergier, B.; Beylot-Barry, M.; Merlio, J.P. MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type. J. Invest. Derm. 2012, 132, 2118–2120. [Google Scholar] [CrossRef] [Green Version]
  161. Menguy, S.; Gros, A.; Pham-Ledard, A.; Battistella, M.; Ortonne, N.; Comoz, F.; Balme, B.; Szablewski, V.; Lamant, L.; Carlotti, A.; et al. MYD88 Somatic Mutation Is a Diagnostic Criterion in Primary Cutaneous Large B-Cell Lymphoma. J. Investig. Derm. 2016, 136, 1741–1744. [Google Scholar] [CrossRef] [Green Version]
  162. Schrader, A.M.R.; Jansen, P.M.; Vermeer, M.H.; Kleiverda, J.K.; Vermaat, J.S.P.; Willemze, R. High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. Am. J. Surg. Pathol. 2018, 42, 1488–1494. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  163. Fox, L.C.; Yannakou, C.K.; Ryland, G.; Lade, S.; Dickinson, M.; Campbell, B.A.; Prince, H.M. Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy. Int J. Mol. Sci. 2018, 19, 1758. [Google Scholar] [CrossRef] [Green Version]
  164. Mitteldorf, C.; Berisha, A.; Pfaltz, M.C.; Broekaert, S.M.C.; Schön, M.P.; Kerl, K.; Kempf, W. Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets. Am. J. Surg. Pathol. 2017, 41, 998–1004. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  165. Villano, J.L.; Koshy, M.; Shaikh, H.; Dolecek, T.A.; McCarthy, B.J. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br. J. Cancer 2011, 105, 1414–1418. [Google Scholar] [CrossRef] [PubMed]
  166. O’Neill, B.P.; Decker, P.A.; Tieu, C.; Cerhan, J.R. The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin’s lymphoma. Am. J. Hematol. 2013, 88, 997–1000. [Google Scholar] [CrossRef] [Green Version]
  167. Batchelor, T.T. Primary central nervous system lymphoma. Hematol. Am. Soc. Hematol. Educ. Program 2016, 2016, 379–385. [Google Scholar] [CrossRef] [Green Version]
  168. Bhagavathi, S.; Wilson, J.D. Primary central nervous system lymphoma. Arch. Pathol. Lab. Med. 2008, 132, 1830–1834. [Google Scholar] [CrossRef]
  169. Liu, J.; Wang, Y.; Liu, Y.; Liu, Z.; Cui, Q.; Ji, N.; Sun, S.; Wang, B.; Sun, X. Immunohistochemical profile and prognostic significance in primary central nervous system lymphoma: Analysis of 89 cases. Oncol. Lett. 2017, 14, 5505–5512. [Google Scholar] [CrossRef] [Green Version]
  170. Shi, Q.Y.; Feng, X.; Bao, W.; Ma, J.; Lv, J.H.; Wang, X.; Rao, Q.; Shi, Q.L. MYC/BCL2 Co-Expression Is a Stronger Prognostic Factor Compared With the Cell-of-Origin Classification in Primary CNS DLBCL. J. Neuropathol. Exp. Neurol. 2017, 76, 942–948. [Google Scholar] [CrossRef]
  171. Brunn, A.; Nagel, I.; Montesinos-Rongen, M.; Klapper, W.; Vater, I.; Paulus, W.; Hans, V.; Blümcke, I.; Weis, J.; Siebert, R.; et al. Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC(low)BCL2(low) subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas. Acta Neuropathol. 2013, 126, 603–605. [Google Scholar] [CrossRef]
  172. Nosrati, A.; Monabati, A.; Sadeghipour, A.; Radmanesh, F.; Safaei, A.; Movahedinia, S. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type. Ann. Hematol. 2019, 98, 169–173. [Google Scholar] [CrossRef] [PubMed]
  173. Tapia, G.; Baptista, M.J.; Muñoz-Marmol, A.M.; Gaafar, A.; Puente-Pomposo, M.; Garcia, O.; Marginet-Flinch, R.; Sanz, C.; Navarro, J.T.; Sancho, J.M.; et al. MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system. APMIS 2015, 123, 596–603. [Google Scholar] [CrossRef] [PubMed]
  174. Kim, S.; Nam, S.J.; Kwon, D.; Kim, H.; Lee, E.; Kim, T.M.; Heo, D.S.; Park, S.H.; Kim, C.W.; Jeon, Y.K. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system. BMC Cancer 2016, 16, 363. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  175. Morin, R.D.; Johnson, N.A.; Severson, T.M.; Mungall, A.J.; An, J.; Goya, R.; Paul, J.E.; Boyle, M.; Woolcock, B.W.; Kuchenbauer, F.; et al. Somatic mutations altering EZH2(Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 2010, 42, 181–185. [Google Scholar] [CrossRef]
  176. Berg, T.; Thoene, S.; Yap, D.; Wee, T.; Schoeler, N.; Rosten, P.; Lim, E.; Bilenky, M.; Mungall, A.J.; Oellerich, T.; et al. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis. Blood 2014, 123, 3914–3924. [Google Scholar] [CrossRef] [Green Version]
  177. Guo, S.; Bai, Q.; Rohr, J.; Wang, Y.; Liu, Y.; Zeng, K.; Yu, K.; Zhang, X.; Wang, Z. Clinicopathological features of primary diffuse large B-cell lymphoma of the central nervous system—Strong EZH2 expression implying diagnostic and therapeutic implication. Apmis 2016, 124, 1054–1062. [Google Scholar] [CrossRef] [PubMed]
  178. Pellissery, S.; Richter, J.; Haake, A.; Montesinos-Rongen, M.; Deckert, M.; Siebert, R. Somatic mutations altering Tyr641 of EZH2 are rare in primary central nervous system lymphoma. Leuk. Lymphoma 2010, 51, 2135–2136. [Google Scholar] [CrossRef]
  179. Braggio, E.; McPhail, E.R.; Macon, W.; Lopes, M.B.; Schiff, D.; Law, M.; Fink, S.; Sprau, D.; Giannini, C.; Dogan, A.; et al. Primary central nervous system lymphomas: A validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens. Clin. Cancer Res. 2011, 17, 4245–4253. [Google Scholar] [CrossRef] [Green Version]
  180. Sung, C.O.; Kim, S.C.; Karnan, S.; Karube, K.; Shin, H.J.; Nam, D.H.; Suh, Y.L.; Kim, S.H.; Kim, J.Y.; Kim, S.J.; et al. Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. Blood 2011, 117, 1291–1300. [Google Scholar] [CrossRef]
  181. Zhou, Y.; Liu, W.; Xu, Z.; Zhu, H.; Xiao, D.; Su, W.; Zeng, R.; Feng, Y.; Duan, Y.; Zhou, J.; et al. Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes. Neoplasia 2018, 20, 1059–1069. [Google Scholar] [CrossRef]
  182. Nayyar, N.; White, M.D.; Gill, C.M.; Lastrapes, M.; Bertalan, M.; Kaplan, A.; D’Andrea, M.R.; Bihun, I.; Kaneb, A.; Dietrich, J.; et al. L265P mutation and. Blood Adv. 2019, 3, 375–383. [Google Scholar] [CrossRef] [Green Version]
  183. Montesinos-Rongen, M.; Godlewska, E.; Brunn, A.; Wiestler, O.D.; Siebert, R.; Deckert, M. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol. 2011, 122, 791–792. [Google Scholar] [CrossRef]
  184. Vater, I.; Montesinos-Rongen, M.; Schlesner, M.; Haake, A.; Purschke, F.; Sprute, R.; Mettenmeyer, N.; Nazzal, I.; Nagel, I.; Gutwein, J.; et al. The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. Leukemia 2015, 29, 677–685. [Google Scholar] [CrossRef]
  185. Lionakis, M.S.; Dunleavy, K.; Roschewski, M.; Widemann, B.C.; Butman, J.A.; Schmitz, R.; Yang, Y.; Cole, D.E.; Melani, C.; Higham, C.S.; et al. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. Cancer Cell 2017, 31, 833–843.e5. [Google Scholar] [CrossRef] [Green Version]
  186. Todorovic Balint, M.; Jelicic, J.; Mihaljevic, B.; Kostic, J.; Stanic, B.; Balint, B.; Pejanovic, N.; Lucic, B.; Tosic, N.; Marjanovic, I.; et al. Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses. Int. J. Mol. Sci. 2016, 17, 683. [Google Scholar] [CrossRef] [Green Version]
  187. Zheng, M.; Perry, A.M.; Bierman, P.; Loberiza, F.; Nasr, M.R.; Szwajcer, D.; Del Bigio, M.R.; Smith, L.M.; Zhang, W.; Greiner, T.C. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma. Neuropathology 2017, 37, 509–516. [Google Scholar] [CrossRef]
  188. Cobbers, J.M.; Wolter, M.; Reifenberger, J.; Ring, G.U.; Jessen, F.; An, H.X.; Niederacher, D.; Schmidt, E.E.; Ichimura, K.; Floeth, F.; et al. Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL. Brain Pathol. 1998, 8, 263–276. [Google Scholar] [CrossRef] [PubMed]
  189. Nakamura, T.; Tateishi, K.; Niwa, T.; Matsushita, Y.; Tamura, K.; Kinoshita, M.; Tanaka, K.; Fukushima, S.; Takami, H.; Arita, H.; et al. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol. Appl. Neurobiol. 2016, 42, 279–290. [Google Scholar] [CrossRef] [PubMed]
  190. Arai, M.; Sasaki, A.; Saito, N.; Nakazato, Y. Immunohistochemical analysis of cleaved caspase-3 detects high level of apoptosis frequently in diffuse large B-cell lymphomas of the central nervous system. Pathol. Int. 2005, 55, 122–129. [Google Scholar] [CrossRef]
  191. Chang, F.; Lee, J.T.; Navolanic, P.M.; Steelman, L.S.; Shelton, J.G.; Blalock, W.L.; Franklin, R.A.; McCubrey, J.A. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy. Leukemia 2003, 17, 590–603. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  192. Munch-Petersen, H.D.; Asmar, F.; Dimopoulos, K.; Areškevičiūtė, A.; Brown, P.; Girkov, M.S.; Pedersen, A.; Sjö, L.D.; Heegaard, S.; Broholm, H.; et al. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy. Acta Neuropathol. Commun. 2016, 4, 40. [Google Scholar] [CrossRef] [Green Version]
  193. Zorofchian, S.; El-Achi, H.; Yan, Y.; Esquenazi, Y.; Ballester, L.Y. Characterization of genomic alterations in primary central nervous system lymphomas. J. Neurooncol. 2018, 140, 509–517. [Google Scholar] [CrossRef]
  194. Gandhi, M.K.; Hoang, T.; Law, S.C.; Brosda, S.; O’Rourke, K.; Tobin, J.W.D.; Vari, F.; Murigneux, V.; Fink, L.; Gunawardana, J.; et al. EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood 2021, 137, 1468–1477. [Google Scholar] [CrossRef]
  195. Chapuy, B.; Roemer, M.G.; Stewart, C.; Tan, Y.; Abo, R.P.; Zhang, L.; Dunford, A.J.; Meredith, D.M.; Thorner, A.R.; Jordanova, E.S.; et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 2016, 127, 869–881. [Google Scholar] [CrossRef] [Green Version]
  196. Berghoff, A.S.; Ricken, G.; Widhalm, G.; Rajky, O.; Hainfellner, J.A.; Birner, P.; Raderer, M.; Preusser, M. PD1(CD279) and PD-L1(CD274, B7H1) expression in primary central nervous system lymphomas(PCNSL). Clin. Neuropathol. 2014, 33, 42–49. [Google Scholar] [CrossRef] [PubMed]
  197. Furuse, M.; Kuwabara, H.; Ikeda, N.; Hattori, Y.; Ichikawa, T.; Kagawa, N.; Kikuta, K.; Tamai, S.; Nakada, M.; Wakabayashi, T.; et al. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma. BMC Cancer 2020, 20, 277. [Google Scholar] [CrossRef] [PubMed]
  198. Grommes, C.; Nayak, L.; Tun, H.W.; Batchelor, T.T. Introduction of novel agents in the treatment of primary CNS lymphoma. Neuro. Oncol. 2019, 21, 306–313. [Google Scholar] [CrossRef] [PubMed]
  199. Ou, A.; Sumrall, A.; Phuphanich, S.; Spetzler, D.; Gatalica, Z.; Xiu, J.; Michelhaugh, S.; Brenner, A.; Pandey, M.; Kesari, S.; et al. Primary CNS lymphoma commonly expresses immune response biomarkers. Neurooncol. Adv. 2020, 2, vdaa018. [Google Scholar] [CrossRef]
  200. Delsol, G.; Lamant, L.; Mariamé, B.; Pulford, K.; Dastugue, N.; Brousset, P.; Rigal-Huguet, F.; al Saati, T.; Cerretti, D.P.; Morris, S.W.; et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood 1997, 89, 1483–1490. [Google Scholar] [CrossRef] [PubMed]
  201. Gascoyne, R.D.; Lamant, L.; Martin-Subero, J.I.; Lestou, V.S.; Harris, N.L.; Müller-Hermelink, H.K.; Seymour, J.F.; Campbell, L.J.; Horsman, D.E.; Auvigne, I.; et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: Report of 6 cases. Blood 2003, 102, 2568–2573. [Google Scholar] [CrossRef] [Green Version]
  202. De Paepe, P.; Baens, M.; van Krieken, H.; Verhasselt, B.; Stul, M.; Simons, A.; Poppe, B.; Laureys, G.; Brons, P.; Vandenberghe, P.; et al. ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 2003, 102, 2638–2641. [Google Scholar] [CrossRef] [Green Version]
  203. Adam, P.; Katzenberger, T.; Seeberger, H.; Gattenlöhner, S.; Wolf, J.; Steinlein, C.; Schmid, M.; Müller-Hermelink, H.K.; Ott, G. A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2; 5)(p23; q35) chromosome translocation. Am. J. Surg. Pathol. 2003, 27, 1473–1476. [Google Scholar] [CrossRef]
  204. Onciu, M.; Behm, F.G.; Downing, J.R.; Shurtleff, S.A.; Raimondi, S.C.; Ma, Z.; Morris, S.W.; Kennedy, W.; Jones, S.C.; Sandlund, J.T. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: Report of 2 cases. Blood 2003, 102, 2642–2644. [Google Scholar] [CrossRef] [PubMed]
  205. Stachurski, D.; Miron, P.M.; Al-Homsi, S.; Hutchinson, L.; Harris, N.L.; Woda, B.; Wang, S.A. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma with a complex karyotype and cryptic 3’ ALK gene insertion to chromosome 4 q22-24. Hum. Pathol. 2007, 38, 940–945. [Google Scholar] [CrossRef]
  206. Van Roosbroeck, K.; Cools, J.; Dierickx, D.; Thomas, J.; Vandenberghe, P.; Stul, M.; Delabie, J.; De Wolf-Peeters, C.; Marynen, P.; Wlodarska, I. ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. Haematologica 2010, 95, 509–513. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  207. D’Amore, E.S.; Visco, C.; Menin, A.; Famengo, B.; Bonvini, P.; Lazzari, E. STAT3 pathway is activated in ALK-positive large B-cell lymphoma carrying SQSTM1-ALK rearrangement and provides a possible therapeutic target. Am. J. Surg. Pathol. 2013, 37, 780–786. [Google Scholar] [CrossRef] [PubMed]
  208. Orwat, D.E.; Batalis, N.I. Intravascular large B-cell lymphoma. Arch. Pathol. Lab. Med. 2012, 136, 333–338. [Google Scholar] [CrossRef]
  209. Shimada, K.; Yoshida, K.; Suzuki, Y.; Iriyama, C.; Inoue, Y.; Sanada, M.; Kataoka, K.; Yuge, M.; Takagi, Y.; Kusumoto, S.; et al. Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma. Blood 2021, 137, 1491–1502. [Google Scholar] [CrossRef]
Table
Table 1. Diffuse large-B cell lymphomas reviewed in this paper.
Table 1. Diffuse large-B cell lymphomas reviewed in this paper.
Diffuse Large B-Cell Lymphoma, Nos
High Grade B-Cell Lymphoma
   High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement
   High grade B-cell lymphoma, NOS
   Burkitt lymphoma
   Burkitt-like lymphoma with 11q aberration
T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma at Specific Sites
   Large B-cell lymphoma with IRF4 rearrangement (LBCL-IRF4)
   Primary mediastinal (thymic) large B-cell lymphoma (PMBL)
   Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT)
   Primary diffuse large B-cell lymphoma of the central nervous system (CNS-DLBCL)
Large B-Cell Lymphomas with Plasmacytic Differentiation
   ALK-positive large B-cell lymphoma (ALK + DLBCL)
   Intravascular large B-cell lymphoma (IVLBCL)
Table
Table 2. Main molecular alterations characterizing diffuse large-B-cell lymphoma variants.
Table 2. Main molecular alterations characterizing diffuse large-B-cell lymphoma variants.
Entity/CategoryMolecular Alterations
TranslocationsCNVMutations
DLBCL-NOSMYC translocations (10–15%) with IGH, IGL, IGK, PAX5, BCL6, BCL11A, IKZF1 (IKAROS), and BTG1.PD-L1/L2 amplification (20–25%)MYD88L265P, CD79B, NOTCH1, EZH2, SGK1, TET2, TP53
DLBCL-NOS, ABC-subtypet(14; 3) (q27; q32)/IGH-BCL6 (30%) MYD88 (20), CD79A/B (20%), CARD11 (10%), MALT1, BCL10, TNFAIP3, PRDM1/BLIMP1 (30%), MYD88, PIM1, NOTCH2
DLBCL-NOS, GCB-subtypet(14; 18) (q21; q32)/IGH-BCL2 EZH2 (20%), EP300, CREBBP, KMT2D, GNA13, GNAI2, SIPR2, BRAF, STAT3, RHOA, SGK1, CARD11, NFKBIE, NFKBIA, CD83, CD58, CD70, BCL2, MEF2B, IRF8, TNFSF14, HCNV1, PTEN, TP53, CDKN2A
HGBL-DH (MYC/BCL2)MYC translocations with 14q32 (IGH; 39%), 22q11 (IGL; 6%), 2p12 (IGK, 7%), 1p36, 3p25, 3q27(BCL6), 4p13, 5q13, 9p13 (PAX5), 12p11, and 13q31.,Gains of chromosomes 7, 8, 11, 12, 18, 20 and X, and losses of 3q, 6q, and 15q26CREBBP (80%), BCL2 (60%), KMT2D (60%), MYC (45%), EZH2 (40%), IGLL5 (45%), FOX01 (30%), ID3, CCND3, TCF3, EP300, MEF2B, SGK1, SOCS1, CCND3, TP53.
HGBL-DH (MYC/BCL6)MYC translocations with 14q32 (IGH), 22q11 (IGL), 2p12 (IGK), 1p36, 3p25, 3q27(BCL6), 4p13, 5q13, 9p13 (PAX5), 12p11, and 13q31
HGBL-THMYC translocations with 14q32 (IGH), 22q11 (IGL), 2p12 (IGK), 1p36, 3p25, 3q27(BCL6), 4p13, 5q13, 9p13 (PAX5), 12p11, and 13q31 TP53, BCL2, CCND3, CREBBP, EZH2, ID3, KMT2D, MYC, FOXO1, and SOCS1.
HGBCL, NOS Amplifications of MYC, BCL2, or BCL6.Isolated MYC (40%), BCL2, or BCL6 breakpoints. Simultaneous rearrangement of BCL6 and BCL2.
BLt(8; 14) (q24; q32) IGH/MYC (80%), t(2; 8)(q12;24) IGK/MYC (15%) and t(8; 22) (q24;11) IGL/MYC (5%)1q gainTCF3 or its negative regulator ID3 (40–70%), CCDN3 (38%), GNA13, RET, PIK3R1, DDX3X, FBXO11, SWI/SNF genes, ARID1A, SMARCA4, BCL7A, BCL6, DNMT1, SNTB2, CTCF, IGLL5, BACH2, TP53 (40%)
BLL, 11Q Gains of 12q12-q21.1, losses of 6q12.1-q21.1Mutations involving BTG2, DDX3X, ETS1, EP300, and GNA13
THRLBCLPAX5/IGH rearrangementsGains of 2p16.1 and PD-L1/PD-L2 (64%). Losses of 2p11.2, and 9p11.2 JUNB, DUSP2, SGK1, SOC1
LBCL-IRF4IRF4, BCL6 rearrangements
IRF4/IGH fusions		Gains of 7q32.1-qter, 11q22.3-qter, and Xq28
Losses of 6q13–16.1, 15q14–22.3, 17p, and TP53		CARD11, CD79B, and MYD8
PMBL Amplification of REL (75%) and BCL11A (50%)
Deletions of NFKBIE (20%)
9p24.1 (70%)		TNFAIP3 (60%), GNA13 (50%), BCL6 (50%), XPO1(35%), STAT6 (72%), SOCS1 (45%), PTPN1 (25%), IL4R (24,2%), CIITA, CD58, B2, PD-L1, and PD-L2
PCDLBCL-LTTranslocations involving BCL6, MYC, and IGH
PD-L1/PD-L2 (40%), IGH-IRF8		Amplification of BCL2, 18q21
Loss of CDKN2A and CDKN2B, 6q deletions (loss of BLIMP1) 		MYD88 (75%), TNFAIP3 (40%), CD79A, CD79B, CARD11, NFKBIE
CNS-DLBCLMYC, BCL2, and BCL6 translocationsGains 18q21.33–23, 10q23.21 and 9p24.1. Deletions of 6p21, 6q and 9q21.3 PIM1 (77%), MYD88 (64%), CD79B (59%), CDKN2A, IRF4, CARD11, CD79A, ITPKB, KMT2D, CREBBP, MEF2B, CCND1, SOCS1, STAT6, STAT3, CD58, CIITA, GNA13, MYC, RHO, BLC2, PTEN, and SMO
ALK+ DLBCLt(2; 17) (p23; q23) Clathrin-ALK (85–90%)
t(2; 5) (p23; q35) NPM-ALK, SEC31A-ALK, SQSTM1-ALK, RANBP2-ALK, IGL-ALK, and CLTC-ALK 		Insertion of the ALK gene into 4q22–24
IVLBCLPD-L1/PD-L2 rearrangements PIM1 (67%), MYD88 (44–59%), CD79B (26–67%), PRDM1 (44%), BTG2 (22%) and EZH2 (4%).
DLBCL-NOS: Diffuse large B-cell lymphoma, not otherwise specified; DLBCL-NOS, ABC-subtype; Diffuse large B-cell lymphoma, not otherwise specified, activated B-cell phenotype; DLBCL-NOS, GCB-subtype: Diffuse large B cell lymphoma, not otherwise specified, germinal-center B-cell phenotype; HGBL-DH (MYC/BCL2): High grade B-cell lymphoma with MYC and BCL2 rearrangement; HGBL-DH (MYC/BCL6): High grade B-cell lymphoma with MYC and BCL6 rearrangement; HGBL-TH: triple-hit high-grade large B-cell lymphoma; HGBL, NOS: High grade B-cell lymphoma, not-otherwise specified; BL: Burkitt Lymphoma; BL-11QBurkitt-like lymphoma with 11q aberration; THRLBCL: T-cell/Histiocyte-Rich Large B-cell Lymphoma; LBCL-IRF4: Large B-cell lymphoma with IRF4 rearrangement; PMBL: Primary mediastinal (thymic) large B-cell lymphoma; PCDLBCL-LT: Primary cutaneous diffuse large B-cell lymphoma, leg type; CNS-DLBCL: Primary diffuse large B-cell lymphoma of the central nervous; ALK + DLBCL: ALK-positive large B-cell lymphoma; IVLBCL: Intravascular large B-cell lymphoma.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Onaindia, A.; Santiago-Quispe, N.; Iglesias-Martinez, E.; Romero-Abrio, C. Molecular Update and Evolving Classification of Large B-Cell Lymphoma. Cancers 2021, 13, 3352. https://doi.org/10.3390/cancers13133352

AMA Style

Onaindia A, Santiago-Quispe N, Iglesias-Martinez E, Romero-Abrio C. Molecular Update and Evolving Classification of Large B-Cell Lymphoma. Cancers. 2021; 13(13):3352. https://doi.org/10.3390/cancers13133352

Chicago/Turabian Style

Onaindia, Arantza, Nancy Santiago-Quispe, Erika Iglesias-Martinez, and Cristina Romero-Abrio. 2021. "Molecular Update and Evolving Classification of Large B-Cell Lymphoma" Cancers 13, no. 13: 3352. https://doi.org/10.3390/cancers13133352

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop